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 ABSTRACT 
Malignant esophageal tumors are among the most severe cancers. Only about 30% of the 
patients are suitable for curative treatment at diagnosis. The treatment is extremely 
demanding and unfortunately has disappointing results. The staging of disease and the 
treatment for cancer of the esophagus and gastroesophageal junction need to be improved. It 
is currently well established that neoadjuvant therapy, either with chemotherapy or with 
combined chemo- and radiotherapy, followed by surgery, offers a better chance for a cure in 
stage II and III esophageal and gastroesophageal junction cancer, than surgery alone. Data 
directly comparing neoadjuvant chemotherapy and chemoradiotherapy are scarce and it is 
debatable which of these neoadjuvant treatment concepts offers the best chance for long-term 
survival.  
This thesis aims to improve the knowledge about neoadjuvant treatment in the curative 
treatment of esophageal cancer. Papers I and III were based on the Neoadjuvant 
Chemotherapy versus Chemoradiotherapy in Resectable Cancer of the Esophagus and Gastric 
Cardia (NeoRes) trial, which was performed in Norway and Sweden during the period 2006–
2013. Patients with resectable squamous cell carcinoma or adenocarcinoma of the esophagus 
or gastroesophageal junction were randomized to either preoperative chemotherapy or 
preoperative combined chemoradiotherapy followed by surgical resection. Paper I showed an 
increased risk for severe postoperative complications after chemoradiotherapy compared to 
chemotherapy. In paper III we found that neoadjuvant chemoradiotherapy significantly 
increases the proportion of complete histological response, increases the occurrence of N0 
lymph-node status, and increases the R0 resection rate, but there was no difference in overall 
survival compared to neoadjuvant chemotherapy.  
Paper II is a retrospective cohort study of patients with cancer of the esophagus or gastro-
esophageal junction, who was reconstructed with cervical anastomosis. The planned radiation 
dose to the site of the cervical anastomosis on the gastric fundus was estimated for each 
patient. This study suggests that nCRT exposes the future anastomotic site to doses of 
radiation that may impair healing of the subsequent cervical anastomosis. Our data further 
suggest that nCRT may increase the severity of cervical anastomotic complications.  
Paper IV is a prospective population-based cohort study including all patients who underwent 
an esophagectomy operation due to cancer in Sweden, excluding T1N0, recorded in the 
Swedish National Register for Esophageal and Gastric Cancer, 2006-2014. The results 
showed that neoadjuvant chemoradiotherapy increases local tumor control, represented by 
increased R0 resection rates and pathological node-negative disease both compared to 
surgery alone and chemotherapy. For patients with the histological subtype squamous cell 
carcinoma, neoadjuvant treatment increases long-term survival but also increases the risk of 
postoperative morbidity and mortality compared to surgery alone. Neither of the two 
neoadjuvant treatment options seem to improve survival in adenocarcinomas, compared to 
surgery alone, in an unselected population of patients.   
©
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1 INTRODUCTION 
1.1 EPIDEMIOLOGY OF ESOPHAGEAL CANCER 
Esophageal cancer is a rare disease but it is the sixth most common cause of cancer death in 
the world, over the past decades the incidence has changed. There are about 500,000 patients 
diagnosed each year worldwide (1, 2). The most common histological types are squamous 
cell carcinoma (SCC) and adenocarcinoma (AC) representing more than 90% of the tumors. 
Less frequent types are melanoma, leiomyosarcoma, malignant neuroendocrine tumors and 
lymphomas. 
The incidence of AC is rising faster than any other malignancy in the Western world and at 
the same time the incidence for SCC is slowly decreasing (3-5). The causes of these changes 
are not completely known. SCC is more common in developing countries and is associated 
with smoking, alcohol consumption and low socioeconomic status. SCC is still the most 
common histology but in the western world AC now comprises the majority of cases (6). 
Increasing prevalence of obesity and gastroesophageal reflux explains some of the increase. 
Oxidative stress and chronic inflammation in the mucous membrane of the esophagus seems 
to be related to the development of both AC and SCC but through different pathways (7, 8). 
In Sweden men currently have an incidence of 3.9/100,000 for AC and 1.8/100,000 for SCC. 
The incidence for women in Sweden is 1.8/100,000 for AC and 1.0/100,000 for SCC. The 
reasons for the difference between the genders are mainly unknown (9).  
Barrett’s columnar lined esophagus is a condition which is characterized by intestinal 
metaplasia in the distal esophagus recognized by endoscopy and verified with biopsy (10). In 
Barrett’s esophagus the normal squamous cell epithelium has been replaced by metaplastic 
columnar epithelium, the type of epithelium normally found in the ileum and colon. This is 
thought to be caused by long-term exposure to content from the stomach due to reflux. The 
condition is associated with an increased risk of developing AC from 0.1-6% per year (11, 
12). Patients with Barrett´s esophagus undergo regular endoscopies in order to avoid the 
development of cancer. Surveillance programs to detect the condition among risk patients 
have been suggested but are not commonly used (13).    
1.2 CLINICAL PRESENTATION AND WORK-UP 
The most important symptom of esophageal cancer is a problem with swallowing, so-called 
dysphagia, which occurs when the tumor engages about 2/3 of the circumference of the 
lumen. Initially solid foods are difficult to swallow; eventually this progresses to include 
fluids. Patients often lose weight, sometimes leading to sarcopenia. Other symptoms can 
include dyspnea, epigastric or retrosternal pain, persistent cough, respiratory symptoms, or 
hoarseness. The investigation starts with an endoscopic examination of the esophagus, and 
stomach (esophagogastroduodenoscopy). Biopsies are taken for cytological evaluation, which 
concludes the diagnosis. Before treatment the patient is examined with computed tomography 
(CT) of the chest and abdomen to evaluate the tumor and screen for metastases and enlarged 
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lymph nodes (N-stage). Endoscopic ultrasound has a slightly higher accuracy for determining 
N-stage compared to CT (14). The clinical tumor stage (T-stage) is assessed with the use of 
computed tomography and endoscopic ultrasound. Fluorodeoxyglucose (FDG)-positron 
emission tomography (PET) is a nuclear functional imaging technique that can measure the 
local metabolic activity in the body. It can be used to find metastases from cancer and also to 
evaluate response to an oncological treatment. FDG-PET can be combined with a computed 
tomography to create three-dimensional images. In esophageal cancer FDG-PET-CT is 
sometimes used for staging the disease preoperatively (15). In patients with advanced tumor, 
stages T3-T4, in the GEJ a laparoscopy can improve the accuracy of the clinical staging. The 
clinically evaluated T-stage is incorrect in about 40% of the patients (16). A higher T-stage is 
associated with decreased survival (17, 18).  
Before the decision about therapy can be made the patients need a thorough physical 
examination and control of comorbidities. An exercise stress test on a bicycle gives a measure 
of the physical performance level. Spirometry is used to evaluate the pulmonary function. In 
many cases the patients are unfortunately not fit enough for surgery, alternatively the tumor 
growth is locally advanced or has distant metastases. Palliative oncological treatment and best 
supportive care will then be applied. 
1.3 SURGICAL TREATMENT 
Surgical resection, when possible, has been the accepted first treatment choice for decades. 
The esophagectomy is technically advanced and has one of the highest risks of complications 
and postoperative mortality of all surgical procedures but it offers the best chance for long-
term survival (4, 19).  
Superficial tumors that do not penetrate through the submucosa can be removed with 
endoscopic resection with similar chances of long-term survival as esophagectomy (20). 
Endoscopic mucosal resection (EMR), first developed in Japan for early gastric cancers, is 
now used worldwide for removal of adenomas and local tumors in the rectum, colon and the 
esophagus. The lesion is identified and demarked, and then a submucosal injection is used to 
lift the mucosa from the submucosa before resection with a snare through an endoscope. An 
alternative technique is the endoscopic submucosal dissection (ESD) which has been reported 
to increase the chance for en-bloc complete resection of the neoplastic lesions (21). ESD 
applies endoscopic dissection with a diathermic knife instead of the snare used in EMR, 
making resection of larger lesions possible. T1a tumors have a very low risk of spreading to 
local lymph nodes and it is feasible to treat them with endoscopic resection. T1b tumors have 
increased risk of lymph node metastases, therefore esophagectomy with lymph node 
dissection is recommended in these cases. Endoscopic resection has the advantage of sparing 
the patient from an esophagectomy. The R0 resection rate is around 90%, or higher for 
tumors smaller than 25 mm diameter, and the risk for perforation is around 1% (22). 
Definitive chemoradiotherapy for stage I esophageal SCC has been investigated in Japan with 
a 4-year survival rate of 80.5% (23). 
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The history of the esophagectomy started in the late 19th century with Theodor Billroth, who 
performed the first resection of the esophagus via the abdomen in 1871. The first successful 
resection of the thoracic part of the distal esophagus was performed in 1913 by Franz J. A. 
Torek in New York. The patient was a 67-year-old female with a distal squamous cell 
carcinoma. The tumor was exposed through a left-side thoracotomy in the seventh intercostal 
space. The tumor was removed and the proximal part of the esophagus was brought out 
subcutaneously below the neck. The proximal esophagus was connected with a gastrostomy 
rubber tube and the patient could eat orally. This was a new approach in entering the thoracic 
cavity and a major surgical breakthrough. The patient was cured from the cancer and lived for 
12 more years (24, 25). 
The overall 5-year survival rate for esophageal cancer has increased from less than 5% in the 
1970s and is currently 15-25% (26, 27). The reasons for the poor prognosis are that the 
disease is often disseminated by the time of detection, because early stage disease rarely 
causes symptoms, and that the curative treatment is extremely demanding and often not 
tolerable for elderly and chronically ill patients (19). Less than 50% of all patients are suitable 
for treatment with curative intent. Surgical resection of the tumors with limited spread offers 
a 5-year survival rate of about 25-30% (28-30). Enhanced recovery programs with 
improvements in perioperative care have been introduced and more patients are now being 
treated in high-volume centers specializing in esophageal cancer, all together leading to 
improved outcomes (31, 32).  
1.3.1 Surgical technique 
Esophagectomy may be performed using a variety of techniques. In order to cure a patient 
from cancer the tumor needs to be removed with a margin of healthy tissue surrounding the 
specimen, in other words an R0 resection. The College of American Pathologists define an 
R0 resection as no tumor cells present at the border of the specimen. The Royal College of 
Pathologists define R0 resection as no tumor cells within 1 mm of the margin (33-35). The 
differences in classification are important when comparing the results of studies. Tumor-free 
circumferential margin is most difficult to achieve whereas the longitudinal margins are 
tumor free in the majority of cases. A so-called R1 resection with microscopically identified 
tumor cells at the resection margin is associated with poor outcome (17, 36). In the situation 
where it is impossible for the surgeon to remove all macroscopically visible tumor the 
resection is defined as R2.  
In Western populations, with the dominance of distal adenocarcinomas, the most used 
technique is the two-stage thoraco-abdominal Ivor Lewis procedure first described in 1946. 
The stomach and distal esophagus are dissected via a laparotomy and the mediastinal part of 
the esophagus through a right-sided thoracotomy. The anastomosis is placed just below the 
thoracic aperture. The advantages of the Ivor Lewis approach are the good access to the 
tumor and lymph nodes in the thorax and decreased risk of recurrent nerve injury compared 
to procedures involving a cervical incision. On the other hand placing the anastomosis in the 
thorax carries the risk of life-threatening mediastinitis in the case of anastomotic failure. The 
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thoracotomy is associated with postoperative pulmonary complications and the proximal 
surgical resection margin is on average shorter than with a cervical incision (37). Transhiatal 
esophagectomy, initially described by Denk in 1913, employs access only through a 
laparotomy and a neck incision and using a cervical anastomosis of the gastric conduit for 
reconstruction. This approach has the benefit of avoiding thoracotomy, leading to less 
pulmonary complications and is often used in patients who are not fit enough for the Ivor 
Lewis esophagectomy. The downside is of course that the dissection of the thoracic part of 
the esophagus is performed from the abdomen with less precise lymph node dissection, 
especially in the mid and upper mediastinum, resulting in fewer resected lymph nodes and, 
with the possible exception of Siewert II junctional cancers, a lower chance for long-term 
survival (38, 39). The cervical approach increases the risk of recurrent nerve injury (40). The 
proximal esophagus is reached through an incision in the neck and the anastomosis is 
constructed here. An advantage with this technique is that in the case of an anastomotic 
leakage it can be drained through the wound on the neck and mediastinitis can in many cases 
be avoided.  
In Asia, with the high incidence of squamous cell carcinoma of the upper and mid esophagus, 
the three-stage esophagectomy with incisions in the right thoracic cavity, abdomen and neck 
with cervical anastomosis is the most common technique. This procedure was first described 
by McKeown in 1976. The advantages with the approach are good access for removing the 
whole esophagus, improved possibilities to perform a radical lymphadenectomy, including 
the option of radical neck dissection, and the placement of the anastomosis out of the thorax 
(41). Disadvantages are increased postoperative morbidity due to the large operating field 
(42). In Asia the three-field lymphadenectomy is widely used, in the western world it is 
mainly applied in cases with known lymph node metastases (43, 44). 
Recently minimally invasive procedures have been developed, using laparoscopic and/or 
thoracoscopic access (45). The techniques correspond to the two-stage Ivor Lewis 
esophagectomy, transhiatal esophagectomy, or the three-field dissection esophagectomy. The 
anastomosis can be constructed in the thorax, using circular or linear stapling technique, or 
hand-sewn in the neck through a cervical incision. Trials show evidence of better short-term 
outcomes after minimally invasive techniques compared to open esophagectomy. In 
particular pulmonary and respiratory complications have been shown to be reduced (46-48). 
Hybrid minimally invasive esophagectomy with laparoscopy and thoracotomy have been 
shown to have good results concerning major pulmonary complications and a decreased rate 
of postoperative mortality compared to surgery alone (SA) (49, 50). Robot-assisted 
esophagectomy has been introduced in some centers and is under development (51, 52).  
The most common technique for reconstruction is the gastric tube conduit. With the use of 
linear staplers a tube is formed of the greater curvature side of the stomach. The conduit is 
then pulled up to the proximal esophagus and an anastomosis is performed in the thorax or in 
the neck. Long term results have been shown to be similar comparing intrathoracic and 
cervical anastomoses in a non-randomized study (53). A potential problem with the use of a 
gastric conduit is that the circulation may be compromised in the proximal part where the 
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anastomosis will be situated. The gastroepiploic artery and vein, and the first two or three 
branches of the right gastric arteries and veins are preserved and the dissection of the major 
curve is made with caution in order to decrease the risk for poor circulation and subsequent 
necrosis in the anastomosis. 
 
Figure 1. A gastric tube during construction. 
When applying a cervical anastomosis the gastric conduit often has to be used in its full 
length, constructing the anastomosis at the most cranial part of the fundus of the stomach, 
where the circulation is most limited. If the conduit can be made longer than needed the most 
cranial few centimetres can be resected. Deficient circulation may account for the increased 
risk of leakage and postoperative stricture, which has been observed in some studies 
comparing cervical and intrathoracic anastomoses (54-56).  Moreover, patients with distal 
tumors being irradiated preoperatively within the context of nCRT, run a risk of receiving 
biologically relevant doses of radiation directly against the gastric fundus, which is 
subsequently used for the anastomosis. Radiotherapy towards distal esophageal tumors is 
administered with relatively generous margins in order to compensate for breathing-related 
movement in the area. The coeliac lymph nodes are also included in the field. Dose planning 
to reduce the dose against heart and lung is performed, but the fundus part of the stomach that 
will be used in the esophagogastrostomy is not actively avoided. This may further increase 
the risk and severity of cervical anastomotic complications, given the already compromised 
circulation of the extended gastric conduit necessary to reach the neck.  
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1.3.2 Postoperative complications 
The perioperative mortality rate after esophagectomy is among the highest of all surgical 
procedures but it has improved over the years, from 29% 1960-1979 to 8.8% 1990-2000 (30, 
57, 58). Hospitals that perform many esophagectomies (high volume centers often defined as 
>10 esophagectomies/year) have better results in terms of both postoperative morbidity and 
mortality as well as long-term survival (32, 59). In high volume centers the perioperative 
mortality is now around 3% (60-62). One study identified an increased use of epidural 
analgesia, bronchoscopy to clear the lungs from secretion, decreased frequency of smoking, 
and less perioperative bleeding as factors associated with less in-hospital mortality after 
esophagectomy (63). The overall rate of postoperative complications is between 40-80% in 
different studies partly depending on definition and method of assessment. American Society 
of Anesthesiologists (ASA) score, male gender, cervical anastomosis, and high age are 
known risk factors for postoperative morbidity and mortality (64, 65). It is difficult to 
compare trials concerning complications due to the different classifications. A standardized 
report system could improve the studies of postoperative outcomes (66). The Esophageal 
Complications Consensus Group has proposed a recommended list of variables and 
definitions of postoperative events that should be recorded in studies after esophagectomy in 
the future (67).  Enhanced recovery programs are now being introduced in many centers. The 
scientific evidence for using these programs is relatively weak but the guidelines in the 
programs are all based on the best available evidence. The programs have probably improved 
the postoperative care and reduced the treatment-related morbidity and mortality (31). 
Anastomotic failure is one of the most severe complications and occurs in about 10% (68) of 
the cases with the Ivor Lewis technique and 15-35% with neck anastomosis, many times with 
complicated postoperative care with single or multi-organ dysfunction or even death as a 
result (55, 56, 64, 69, 70). A leakage from the anastomosis can cause severe mediastinitis 
leading to a large inflammatory response, acute respiratory distress syndrome (ARDS), and 
respiratory insufficiency. It is important to discover an anastomotic leakage early and often to 
treat it aggressively. Endoscopic evaluation of the anastomosis should be done if there is 
suspicion of a leakage. Treatment options are conservative; with the use of stent and 
intrathoracic drainage or lavage, or in the worst case rescue esophagectomy (69, 71, 72). In 
this procedure the anastomosis is removed and the esophagus is deviated in a stoma on the 
neck. 
Pulmonary complications after esophagectomy are a major concern. It occurs in about 20% of 
the patients after open surgery. Pneumonia, intrathoracic abscess, thoracic duct injury, and 
pneumo- or hemothorax are reasons for impaired pulmonary function and sometimes 
respiratory insufficiency requiring ICU-care. Anastomotic failure increases the risk of 
pulmonary problems. A randomized clinical trial (RCT), of minimally invasive techniques 
with thoracoscopy, has shown a decreased rate of pulmonary complications to 9% compared 
to 29% in the open surgery group (46). 
Severe cardiovascular complications after esophagectomy are not common but may cause 
serious problems in 5-10% of the patients. The most common cardiovascular complication is 
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postoperative atrial fibrillation which occurs in 20-25% of the patients (73). Atrial fibrillation 
is sometimes a symptom of another serious complication or a result of either over-hydration 
or hypovolemia. 
Thromboembolic complications are not a major problem in terms of severity of outcome, but 
sufficient prophylaxis with low-molecular weight heparin is indicated, as thromboembolic 
events with minor, or even no symptoms, are very common (58). Bleeding can be a major 
problem intraoperatively by unintended damage to, for example, the azygos vein, inferior 
pulmonary vein, splenic artery or even the aorta. This is however very rare. Delayed 
postoperative bleeding can occur 24-48 hours after surgery and can be caused by slipping of 
ties or clips from gastric vessels or bronchoesophageal arteries or veins.  
Postoperative benign anastomotic strictures occur in about 20% of the patients after hand-
sewn or circular stapled intrathoracic anastomosis. The frequency is around 30% in cervical 
anastomoses (74). The strictures can usually be managed by one or several endoscopic 
balloon dilatations (75).  Postoperative complications and preoperatively decreased arterial 
oxygen levels have been identified as risk factors for postoperative stricture (76). Recurrent 
nerve paralysis occurs in about 15% of the cases and is associated with an increased risk of 
pulmonary complications (40). 
1.4 ALTERNATIVE TREATMENT STRATEGIES 
As prognosis has remained poor despite considerable improvements in perioperative care and 
short-term outcomes, efforts have been made to introduce additional therapy (77). The use of 
adjuvant therapy options have been disappointing; this may be at least partly attributed to 
difficulty in tolerating demanding therapy shortly after esophagectomy (28, 78-82). Cervical 
tumors are uncommon and represent about 5% of all esophageal tumors. The surgical 
approach to the cervical tumor may require laryngopharyngoesophagectomy which disrupts 
the patient´s speech and sometime swallowing. Curatively intended radiotherapy or 
chemoradiotherapy can be used in these patients (83). Radiotherapy is useful in the palliative 
situation for locoregional disease control and symptom relief. During the 1980s some trials 
investigated the effect of neoadjuvant radiotherapy but the results were not comparable to 
those of nCT (84, 85). 
Histological tumor type SCC has been shown to have better response to chemoradiotherapy 
than AC (86, 87). Definitive chemoradiotherapy (dCRT) for SCC gives overall survival rate 
that is on a similar level as after SA and is an alternative treatment regimen for these patients 
(88, 89). A trial evaluating the effect of surgery, compared to continued CRT, in patients who 
responded to nCRT with tumor regression showed no survival benefit from esophagectomy 
(90). A problem with dCRT is that there are no certain ways to determine that a patient has a 
complete response without performing an esophagectomy. A meta-analysis of the diagnostic 
accuracy of endoscopic biopsy and EUS has shown that the technique has high specificity but 
low sensitivity to detect residual disease after neoadjuvant treatment (91). A recent study has 
evaluated the outcomes in 848 patients treated with salvage esophagectomy, due to persistent 
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or recurrent disease within 3 months of dCRT, compared to nCRT and planned esophag-
ectomy. There was an increased risk of anastomotic leak and surgical site infection in the 
salvage esophagectomy group. There was, however, no difference in overall survival or 
postoperative mortality (92).  
1.4.1 Adjuvant treatment 
Adjuvant treatments with chemotherapy or chemoradiotherapy are used in some cases but 
have not been shown to increase survival (78-80, 93, 94). A major problem is that patients 
have traditionally had a long recovery period after esophagectomy, making adjuvant 
oncological treatment not suitable for the majority of patients. In a small trial by Chen and 
colleagues postoperative radiotherapy was given to patients with pathologically confirmed 
lymph node metastases. The results showed decreased risk of recurrence within the irradiated 
field compared to lymph node negative patients who did not receive radiotherapy. There was 
no increase in survival (95).  Most esophageal cancer recurrences are not limited to local 
lymph nodes or anastomotic failure, which makes the rationale for adjuvant radiotherapy 
weak (96). Zahoor and colleagues performed a retrospective study of 375 patients comparing 
primary minimally invasive esophagectomy and adjuvant chemotherapy to nCT and surgical 
resection with similar survival in both groups (97). Most centers do not operate on patients 
with M1 disease, however, a recent study has shown that neoadjuvant treatment followed by 
resection is feasible in some patients (98). Survival after recurrence is very poor but in some 
selected cases a surgical resection and oncological treatment have good results. Risk factors 
for poor outcome are distant recurrence and more than three recurrence locations (99, 100).  
1.5 BASIC RADIOBIOLOGY 
The basics of radiobiology were retrieved from the textbook Basic Clinical Radiobiology 
published by Hodder Arnold (101).  
The principle of combining radiotherapy and surgery has been shown to improve outcomes in 
the treatment of many types of cancer. The idea is that surgery effectively reduces the solid 
tumor mass while the removal of healthy tissue is limited. Radiotherapy decreases residual 
microscopic tumor deposits which the surgical procedure might have left behind. 
Preoperative radiotherapy can reduce tumor size and decrease the number of lymph node 
metastases, increasing the chance for an operation with tumor-free resection margins. 
Theoretically this would lead to a decreased risk of local recurrent disease and increased 
long-term survival.  
The scientific definition of radiation is the transmission of energy in the form of waves or 
particles through space or in a medium. There are different types of radiation, for example: 
electromagnetic radiation, particle radiation and acoustic radiation (including sound). 
Radiation is either ionizing or non-ionizing depending on the level of energy of the particles. 
Ionizing radiation carries enough energy to break chemical bonds inside a cell and ionize 
atoms and molecules; this type of radiation has the potential to affect human cells. In clinical 
radiotherapy high energy electromagnetic radiation (x-rays) are used. The level of effect on 
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biologic tissue depends on the nature of the radiation and the type of tissue exposed. The 
linear energy transfer (LET) is measured in keV/µm and describes how much energy a 
particle transfers to the medium per traversed unit distance. A high LET will deposit its 
energy quickly in the tissue and will not penetrate deeply. Sparsely ionizing radiation 
includes x-rays and gamma rays which are low LET. High LET radiation includes energetic 
neutrons, protons, and heavy charged particles, also called densely ionizing radiations. The 
cut-off value between low and high LET is approximately 10 keV/µm. Radiation dose is 
measured as the amount of absorbed energy per mass of tissue, the unit is Joule/kg also 
known as Gray (Gy). 1 Joule/kg is equal to 1 Gy. In the treatment of most tumors including 
esophageal cancer low LET x-rays are used. Gamma rays are normally only used for head 
and neck cancers. 
Cell damage from ionizing radiation is mainly caused by direct and indirect DNA damage. 
Parts of the radiation will interfere directly with DNA molecules. Recoil electrons will react 
with water and form hydroxyl radicals which in turn can react with target molecules and 
induce cell damage.  The outcome for the cell can be immediate death through apoptosis or 
delayed death. It can also lose its ability for mitosis, either directly or after some divisions. 
Some cells will not respond to the radiation at all and some will adapt and become less 
sensitive to future radiation. The cell is most sensitive to ionizing radiation during the 
proliferation cycle, especially during the mitosis, which is a phase during the cell division. 
Tissues with high proliferation are more sensitive to radiation than tissues with a low 
proliferation rate. In a malignant tumor the cell proliferation is usually very high, making it a 
good target for radiation therapy. Concerning tumor cells, with high frequency of mitosis, cell 
death is defined as loss of reproductive ability. Cells that survive treatment without losing this 
ability are called clonogenic cells. The effects of radiation are immediate but the subsequent 
response in the cell can develop over hours or several years after exposure. Cells that survive 
radiation will repair their DNA in the first hours if no additional damage is caused. A cell 
survival curve describes the fraction of clonogenic cells in relationship to the absorbed dose. 
The shape of the curve differs depending on the type of radiation. A dose response curve 
plots the observed biological effect in an organ and the administered radiation dose. These 
curves depend on the radiation sensitivity of the cells and the proliferation rate. Skin, mucosa 
and intestinal epithelium are sensitive to radiation and are called early responders when 
examining a dose response curve. Late responders include, for example, bone marrow. The 
aim of radiotherapy is to kill the tumor without giving the surrounding tissues radiation doses 
that will lead to serious complications for the patient, the so-called therapeutic ratio. This is 
often described with two sigmoid curves of delivered dose and the tumor control probability 
(TCP) and the normal tissue complication probability (NTCP). Radiotherapy is normally 
delivered with a TCP≥0.5 and a NTCP≤0.05.  
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Figure 2. The principle of the therapeutic ratio. The blue curve represents TCP and the red 
curve NTCP. The interval for treatment is between the curves. 
1.5.1 Fractionated radiotherapy 
There are advantages with administrating radiotherapy in small repeated doses, so-called 
fractionated radiation, instead of one large dose. Fractionating gives an improved ratio of 
TCP and NTCP through five biological factors called the five Rs of radiotherapy.  
1: Radiosensitivity varies in different tissues. 2: Repair of DNA will occur between 
treatments. 3: Repopulation of cells in the tissue between fractions. 4: Redistribution of cells 
in the cell cycle during treatment increases the cell death compared to one single high dose 
session. 5: Reoxygenation of hypoxic cells increases the radiosensitivity in the tissue. Healthy 
tissue is spared through repair of sublethal cell injuries and repopulation of the tissue. The 
tumor damage is increased through reoxygenation and redistribution between fractions.  
1.5.2 Planning external beam radiotherapy 
Radiotherapy is administered to the patient after careful planning of the radiation fields with 
the aim of giving the therapeutic dose to the tumor and at the same time limiting the dose, as 
much as possible, to vital organs. Today this is done with advanced three-dimensional 
computed technology. Computed tomography images of the tumor are used to identify the 
tumor and the critical surrounding organs. The gross tumor target volume (GTV) is the 
palpable, seen or imaged tumor. The clinical target volume (CTV) includes the GTV plus a 
surrounding margin of tissue at high risk of microscopic disease. Finally the planning target 
volume (PTV) is defined. PTV allows for uncertainties in the planning and accounts for the 
physiological movement of organs, for example due to breathing. It is crucial that the CTV is 
adequately treated to achieve a cure for the patients. The PTV is defined in every slice of the 
computed tomography and the organs at risk are also marked. The final treatment plan 
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includes dose distributions and dose-volume histograms of the PTV and the organs at risk. 
For each treatment session the patient is positioned with the help of tattooed marks on the 
skin and the radiotherapy is administered according to the treatment plan. Multiple treatment 
fields are used to give the full dose in the PTV with minimal damage to surrounding tissues.  
1.6 NEOADJUVANT TREATMENT 
With the ambition to improve long-term survival the trend in recent years has been to develop 
effective multimodal treatment including neoadjuvant chemotherapy (nCT), or combined 
neoadjuvant chemoradiotherapy (nCRT), followed by surgery. One concern is the risk of 
increased treatment-related morbidity with the addition of preoperative oncological treatment. 
Neoadjuvant treatment, with nCT or nCRT, followed by radical surgical resection is now the 
gold standard in curatively intended treatment. In RCTs both neoadjuvant regimens have 
been found to increase long-term survival compared to surgical resection alone (87, 102-110). 
Although there have been statistically significant survival benefits the difference is not very 
large compared to SA. In one retrospective study SA was shown to offer a 5-year survival 
rate of 59% for stage 0-II cancers, this number is higher than in many trials of neoadjuvant 
treatment (111). Regarding SCC in the western world, evidence of a beneficial effect on long-
term survival is very well documented for nCRT, while effects are still unclear for nCT (102, 
107, 112, 113). In Asia nCT is the standard treatment in esophageal SCC (114).  
The postoperative morbidity and mortality after nCT has in most trials not been increased 
compared to SA. Postoperative complications after nCRT have in some trials been reported at 
similar numbers as for SA, while some show an increased postoperative risk (68, 86, 87, 115-
119). The addition of preoperative radiotherapy kills malignant cells but the surrounding 
organs also receive radiation to some extent, although efforts are made to keep this to a 
minimum (120). Radiation pneumonitis, pericardial effusion and negative effects on blood 
vessels are a direct effect of radiotherapy and increase with the given dose and the volume of 
lung tissue not spared from doses over 5Gy (121, 122). The neoadjuvant radiation dose is 
most often 35-40 Gy. One study has shown increased local tumor control for patients 
receiving 41-50 Gy when compared to 36 Gy (123). Concerning nCT many different drug 
combinations, doses, and numbers of cycles of chemotherapy have been studied.  
The patients who respond to the neoadjuvant treatment with complete histological response 
or downstaging of the tumor have been shown to have a statistically significant improved 
overall survival rate compared to non-responders and patients not receiving neoadjuvant 
treatment (116, 124-126). The number of lymph nodes resected is a quality measurement of 
the surgery in patients treated with SA. A high number of resected nodes have been 
associated with improved outcome. Neoadjuvant therapy decreases the number of resected 
lymph nodes, malignant as well as benign. This fact changes the way lymph node retrieval 
can be used as a marker for surgical quality (127).  
Until now only two RCTs have been performed comparing nCT to nCRT directly (117, 128). 
Indirect comparisons of the treatments, i.e. comparing the results of a trial of nCT vs. SA 
with a trial of nCRT vs. SA, are common but can have some methodological problems (129). 
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For example assumptions of homogeneity of the included trials can introduce bias, and the 
comparisons of direct and indirect evidence can be inadequate. There are few observational 
studies with prospectively collected data based on a population within a well-defined 
population, evaluating the clinical practice, after the implementation of neoadjuvant 
treatment. Whenever a novel therapeutic concept is developed the question remains how 
effective it will be when applied in routine clinical practice and when offered to significant 
numbers of newly diagnosed patients. Until now large prospective cohort studies have been 
few and incomplete but have been unable to show an overall survival benefit as a result of the 
introduction of neoadjuvant treatment as compared to SA. The possible risk of increased 
perioperative morbidity and mortality has not been evaluated in large prospective cohorts. 
Patients with complete histological response have increased survival, compared to non-
responders, and benefit from neoadjuvant treatment but today we are unable to identify these 
patients beforehand (130-132).  
1.6.1 Cisplatin 
For many years cisplatin has been a cornerstone of the treatment of esophageal cancer. It was 
developed during the 1960s and 1970s after it was discovered that the drug reduced the mass 
of sarcomas in rats (133). Cisplatin was approved for use in testicular and ovarian cancer in 
the United States in 1978 and in Europe in 1979. It is also used in the treatment of lung 
cancer, bladder cancer, cervical cancer, head and neck cancer, and lymphomas. The 
mechanism of action is binding of the platinum atom to DNA bases. This leads to 
crosslinking of the cell DNA which inhibits normal mitosis. The cell will then try to repair 
the DNA and if this doesn’t work the cell will die through apoptosis. Many tumors are 
sensitive to cisplatin initially but develop resistance over time. Side effects include kidney 
damage, hearing loss, nausea and vomiting, and hemolytic anemia. Carboplatin and 
oxaliplatin belong to the same group of platinum-containing anti-cancer drugs as cisplatin 
and are also used in the treatment esophageal cancers. 
1.6.2 5-fluorouracil 
The finding that 5-fluorouracil, also known as 5-FU, inhibited tumor growth in mice was 
described by Heidelberger and colleagues in 1957 (134). 5-FU is a commonly used drug, 
either as a single drug or administered together with other chemotherapy drugs in the 
treatment of, for example; breast cancer, head and neck cancers, anal cancer, and colorectal 
cancer. 5-FU is a so-called anti metabolite and it has more than one mechanism of action. It is 
a thymidylate synthase inhibitor which interrupts the intracellular synthesis of the nucleoside 
thymidine, which leads to cell death through apoptosis. It is also incorporated in the RNA 
molecule and can inhibit the intracellular production of RNA. Common side effects are 
leukopenia, thrombocytopenia, nausea and vomiting, and stomatitis. The risk of neurotoxicity 
increases with the administered dose. Cardiotoxicity is a known but uncommon side effect. 
The risk is higher in patients with previous cardiovascular disease. Patients with the 
metabolic disorder dihydropyrimidine dehydrogenase deficiency can develop life-threatening 
toxicity if exposed to 5-FU. 
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1.6.3 Epirubicin 
Epirubicin is an anthracycline drug which was first approved for use in node-positive breast 
cancer. The first trial in humans was published in 1980 by Bonfante and colleagues (135). It 
can also be used in gastric cancer treatment and for intravesical administration in superficial 
vesical cancer. The mechanism of action is not fully understood. The drug binds to the DNA 
molecule which inhibits DNA and RNA synthesis and triggers DNA cleavage, resulting in 
cell death. The drug also binds to cell membranes and plasma proteins which may increase 
the cytotoxic effects. Side effects that occur are leukopenia, and granulocytopenia with 
subsequent infections, anorexia, dehydration, and mucositis. In the MAGIC trial 
perioperative administration of cisplatin, 5-FU and epirubicin increased long-term survival 
for patients with gastric or esophageal AC.  
1.6.4 Paclitaxel 
Paclitaxel is a member of the taxane drug class and is made from the bark of the rare Pacific 
yew tree. It was discovered in 1962. A semi-synthetic and more potent analogue of the 
chemotherapeutic is docetaxel. The drug inhibits mitotic cell division through interference 
with normal breakdown of microtubules in the cell. It is used in the treatment of several 
cancer types for example; breast, lung, prostate, ovarian, and bladder tumors. Common side 
effects include; neutropenic infections, muscle pain, and hair loss. The CROSS regimen 
nCRT for esophageal cancer includes paclitaxel and carboplatin, in combination with 
concurrent radiotherapy with a total dose of 41.4 Gy (87).  
1.6.5 Tumor regression grade 
Complete histological tumor regression after neoadjuvant treatment is associated with 
improved survival rates compared to partial or no response (124, 136, 137). Tumor regression 
has been shown to be associated with downstaging of the tumor and the interobserver 
agreement between pathologists has been shown to be good (138, 139). With the use of PET-
CT it may be possible to assess the individual patient’s early response to neoadjuvant 
treatment (140-143). In the future the combination of molecular tumor markers, PET-CT, and 
endoscopic evaluation with ultrasound can hopefully be used to evaluate the patient’s 
response (144), and select which patients benefit from completing neoadjuvant therapy and 
which ones may benefit from early interruption and immediate surgery (145). Tumor 
regression grade (TRG) is assessed in the surgical specimen by the pathologist and is based 
on the quota of tumor cells and fibrosis, the lymph node status is not included. The TRG can 
be graded according to several different grading systems (131, 146). Chirieac and colleagues 
described a four-grade scale where TRG 1 represents pathological complete response with no 
remaining tumor cells; TRG 2 represents 1–10% tumor cells; TRG 3, 11–50% tumor cells; 
and TRG 4, >50% tumor cells (124). There is an ongoing study of the accuracy of 
determining residual tumor with endoscopy and endoscopic ultrasound in patients who 
respond to treatment with complete histological response (147). The hypothesis is that it may 
be possible to abstain from surgery in patients with complete response to neoadjuvant 
treatment and instead follow them with regular endoscopic and radiological evaluations. 
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Patients with none or partial response will undergo surgery after the neoadjuvant therapy is 
concluded. Esophagectomy can later be performed in patients with local recurrent disease 
The optimal time between the end of neoadjuvant treatment and surgery has yet to be 
determined. A waiting period of 4-6 weeks has often been used but some data indicate that a 
prolonged wait of 10-12 weeks could increase the TRG (148). Complete histological tumor 
response has been shown to be a prognostic factor for long-term survival, and combined with 
data regarding short-term survival it can be used to evaluate the effect of neoadjuvant 
treatment of esophageal carcinoma (149-151). 
1.6.6 Neoadjuvant chemotherapy vs. surgery alone 
Neoadjuvant chemotherapy for resectable esophageal cancer has been studied since the 
1980s; studies have mostly compared different neoadjuvant treatments to SA without 
supplementary oncological treatment, which has been the standard regimen for many years. 
nCT has been found, in clinical trials, to increase survival without notably increasing the risk 
of postoperative morbidity or mortality when compared to SA (68, 103-105). The results are, 
however, heterogeneous and far from complete but a statistically significantly effect on 
overall survival has been observed in patients with AC, while the data are more ambiguous 
for SCC (103, 107, 125, 152-155). In Japan nCT is the standard treatment since the Japan 
Clinical Oncology Group (JCOG) 9204 trial and the 9907 trial showed increased survival rate 
for patients with SCC compared to SA (80, 93).  
Rates of postoperative morbidity and mortality were similar between groups in most studies. 
Alderson and colleagues compared two cycles of cisplatin/5-FU to 4 cycles of epirubicin/ 
cisplatin/capecitabine.  Capecitabine is an orally administered prodrug which converts 
enzymatically to 5-FU in the body. The longer chemotherapy resulted in increased tumor 
regression grade, and prolonged disease-free survival but overall survival was not improved 
and the treatment-related toxicity was higher (156). Further studies are needed to improve the 
efficacy of the neoadjuvant chemotherapy. 
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Table 1. Selected randomized clinical trials comparing neoadjuvant chemotherapy to surgery 
alone. 
Study Patients Oncological 
treatment  
Results 
Roth (157) 
J Thorac 
Cardiovasc 
Surg 1988. 
39 patients, 
19 had peri- 
operative chemo. 
20 had SA. 
One cycle of 
neoadjuvant cisplatin 
and bleomycin, four 
cycles of vindesine. 
Repeated 
postoperatively. 
Increased survival for responders in 
the chemo-group, median over 20 
months vs. 8.6 months in the 
surgery group. No difference in 
adverse events. 
Nygaard (158) 
World J Surg 
1992. 
186 patients with 
SCC divided into 
four groups; SA, 
nRT, nCRT and 
nCT. 
Two neoadjuvant 
cycles of cisplatin 
and bleomycin. 
The study showed no increase in 
survival comparing the nCT group 
to the SA group.  
Schlag (159) 
Arch Surg 
1992. 
46 patients with 
SCC; 22 to nCT  
and 24 to SA. 
Three neoadjuvant 
cycles of fluorouracil 
and cisplatin. 
Increased survival for responders to 
nCT (median 13 months vs. 5 
months for non-responders). No 
difference in overall survival 
between groups. More adverse 
events in nCT group.  
Law (160) 
J Thorac 
Cardiov Surg 
1997. 
147 patients with 
SCC. 74 received 
nCT and 73 SA. 
Two neoadjuvant 
cycles of cisplatin 
and 5-fluoracil. 
Median survival was 16.8 vs. 13 
months, p=0.17. No difference in 
postoperative mortality. 
Kelsen (152) 
N Engl J Med 
1998. 
440 patients, 236 
with ADC and 
204 with SCC. 
213 received peri-
operative CT  
and 227 SA. 
Three cycles 
neoadjuvant cisplatin 
and fluorouracil plus 
two adjuvant cycles. 
Median survival was 14.9 months in 
the nCT group and 16.1 months in 
SA p=0.53. No difference between 
ADC and SCC. No difference in 
postoperative morbidity and 
mortality. 
Baba (161) 
Dis. of the 
Esophagus 
2000. 
47 patients with 
SCC. 
Two neoadjuvant 
cycles of cisplatin 
and 5-FU and 
leucovirin. 
No increase in survival comparing 
the nCT group to the SA group. No 
statistically significant difference in 
complications. 
Ancona (125) 
Cancer 2001. 
96 patients with  
SCC 
48 had nCT and 
48 had SA.  
Two or three 
neoadjuvant cycles 
of cisplatin and 5- 
fluorouracil. 
No difference in overall survival. 
Patients that responded to 
chemotherapy had a 3-year survival 
rate of 74% vs. 24% for non-
responders and 5-year survival rate 
of 60% vs. 12% p=0.0002. 
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Medical 
research 
council (104) 
Lancet 2002. 
The OEO2 trial.  
802 patients, nCT: 
400 and SA: 402. 
Two neoadjuvant 
cycles of cisplatin 
and 5- fluorouracil. 
Preoperative 
radiation optional. 
Overall survival was better in the 
nCT group HR for death in nCRT 
0·79 (95% CI 0·67–0·93) p=0.004. 
Median survival 16.8 vs. 13.3 
months. No difference in 
postoperative morbidity or 
mortality. 
Cunningham 
(103) N Engl J 
Med. 2006. 
The MAGIC trial.  
503 patients with 
gastric or esopha- 
geal AC randomly 
assigned to nCT 
(n=250) or SA 
(n=253). 
Three cycles of 
epirubicin, cisplatin 
and fluorouracil plus 
three adjuvant cycles. 
Hazard ratio for death after 4 years 
was 0.75 (95% CI, 0.60 to 0.93) 
p=0.009; 5-year survival rate, 36% 
vs. 23%. No difference in 
complications. 
Boonstra 
(153) BMC 
Cancer 2011. 
169 patients with 
SCC in eso-
phagus. 85 nCT 
and 84 SA. 
Two to four cycles of 
cisplatin and 
etoposide. 
5-year survival rate 26% vs. 17%; 
HR for death: 0.71 (95% CI, 0.51 to 
0.98), p=0.03. Pulmonary 
complications 23% after nCT and 
10% after SA, p=0.048. 
Ychou (105) 
J Clin 
Oncology 
2011. 
224 patients with 
ADC in esoph-
agus or 
stomach.113 
 nCT and 111 SA. 
Two or three cycles 
of cisplatin and 5- 
fluorouracil plus 
three or four adjuvant 
cycles. 
5-year survival rate 38% vs. 24%; 
HR for death: 0.69 (95% CI, 0.50 to 
0.95), p=0.02. No difference in 
postoperative morbidity. 
1.6.7 Neoadjuvant chemoradiotherapy vs. surgery alone 
The first trials investigating nCRT in the treatment of esophageal cancer were performed in 
the 1990s. Results show better overall survival after nCRT compared to SA for both AC and 
SCC although the difference is not very large. Perioperative morbidity and mortality has not 
been significantly elevated in most trials, however some studies do show an increased 
postoperative risk compared to SA (68, 106, 162-164). nCRT is currently the gold standard 
treatment for esophageal AC and SCC in many countries including Sweden. In Japan nCRT 
has not been implemented as described above. Several trials have been performed to 
investigate which nCRT regimen is the most effective and which patient category benefits 
most from the treatment (165). Marriette and colleagues showed that nCRT increases the risk 
of postoperative complications without improving survival for patients with stage I-II 
esophageal cancer (118). Induction chemotherapy before nCRT was investigated by Ajani 
and colleagues without showing a survival benefit (166). Two studies have shown an 
increased risk for anastomotic leakage if the anastomosis is placed within a preoperative 
radiation field (167, 168).  
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Table 2. Selected randomized clinical trials comparing neoadjuvant chemoradiotherapy to 
surgery alone. 
Study Patients  Oncological 
treatment 
Results 
Nygaard (158) 
World J Surg 
1992. 
186 patients with 
SCC divided into 
four groups; SA, 
nRT, nCRT and 
nCT. 
Two neo-
adjuvant cycles 
of cisplatin and 
bleomycin and 
35 Gy 
radiotherapy. 
Significantly increased 5-year 
survival rate for patients receiving 
neoadjuvant radiotherapy. 
Le Prise (169) 
Cancer 1994. 
86 patients with 
SCC randomized to 
nCRT (n=41) or SA 
(n=45). 
Two neo-
adjuvant cycles 
of cisplatin and 
5- fluorouracil 
and 20 Gy 
radiotherapy. 
One-year survival rate of 47% in both 
groups. No difference in 
postoperative mortality 8.5% after 
nCRT vs. 7% after SA. 
Apinop (170) 
Hepato-
gastroenterology. 
1994. 
69 patients with 
SCC randomized to 
SA or nCRT.  
Two neo-
adjuvant cycles 
of cisplatin and 
5- fluorouracil 
and 40 Gy 
radiotherapy. 
Slight increase in survival comparing 
the nCRT group to the SA group but 
not significant. No difference in 
complications. 
Walsh (171)  
N Engl J Med. 
1996. 
113 patients 
randomized to 
nCRT (n=58) or SA 
(n=55). 
Two neo-
adjuvant cycles 
of cisplatin and 
5- fluorouracil 
and 40 Gy 
radiotherapy. 
Median survival was 16 months after 
nCRT and 11 months for SA, p=0.01. 
No difference in postoperative 
morbidity. 
Bosset (116) 
N Engl J Med. 
1997. 
282 patients with 
SCC were 
randomized to 
nCRT (n=143) or 
SA (n=139). 
Two neo-
adjuvant cycles 
of cisplatin and 
18.5 Gy 
radiotherapy. 
Median survival was 18.6 months in 
both groups. nCRT group had longer 
disease free survival, p=0.003, 
however postoperative mortality was 
17% vs. 5% for SA, p=0.012. 
Urba (172) 
J Clin Onc. 
2001. 
100 patients with 
SCC or AC were 
randomized to 
nCRT or SA. 
Three neo-
adjuvant cycles 
of cisplatin and 
vinblastine, two 
cycles of 5-FU 
and 45 Gy 
radiotherapy. 
Median survival was 17.6 months in 
the SA group and 16.9 months after 
nCRT. No statistically significant 
difference in frequency of 
complications. 
Lee (173) 
Annals of Onc 
2004. 
101 patients with 
SCC, nCRT (n=51) 
or SA (n=50). 
Two neo-
adjuvant cycles 
of cisplatin, 5-
FU, and 45.6 
Gy concurrent 
radiotherapy. 
Median overall survival: 27.3 months 
in SA and 28.2 months in nCRT, 
p=0.69. No difference in 
postoperative morbidity or mortality. 
Burmeister (86) 
Lancet Onc 
2005. 
256 patients with 
ADC and SCC 
randomly assigned 
to nCRT (n=128) or 
SA (n=128). 
One neo-
adjuvant cycle 
of cisplatin and 
fluoracil and 35 
Gy radio-
therapy. 
No difference in overall survival but 
increased rate of R0 resections 
p=0.0002 and fewer lymph node 
metastasis p=0.003.Increased disease 
free survival for SCC vs. ADC. No 
difference in postoperative 
complications. 
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Natsugoe (174)  
Dis of the Esoph.  
2006. 
45 patients with 
SCC randomized to 
nCRT (n=22) or SA 
(n=23). 
4 cycles of 
Cisplatin, 5-FU, 
40 Gy 
concurrent 
radiotherapy. 
Five-year survival rate: 57% after 
nCRT and 41% after SA, p=0.58. 
Cao (175)  
Dis of the Esoph.  
2009. 
473 patients with 
SCC randomized to 
nRT (n=118), nCT 
(n=119), nCRT 
(n=118) or SA 
(n=118). 
Cisplatin, 5-
Fluorouracil, 
Mitomycin 
week 1+2, 
radiotherapy 
total dose 40 
Gy week 3-6. 
Three-year survival rate: 69.49% 
nRT, 73.73% nCRT vs. 53.38% SA, 
p<0.05. nCT 57.1% no significant 
difference compared to SA. 
van Hagen (87)  
N Engl J Med.  
2012. 
The CROSS trial. 
366 patients with 
ADC or SCC 
randomized to 
nCRT (n=178) and 
SA (n=188). 
Carboplatin and 
paclitaxel for 5 
weeks and 
concurrent 
radiotherapy of 
41.4 Gy. 
Median survival was 49.4 months in 
the nCRT group vs. 24.0 months in 
the SA group. Hazard ratio for death 
in the nCRT group was, 0.657 (95% 
CI 0.495 to 0.871), p=0.003. 
No difference in postoperative 
complications. 
Marriette (118) 
J Clin Onc. 
2014. 
195 patients with 
stage I or II 
esophageal cancer, 
randomized to SA 
(n=97) and nCRT 
(n=98), 70% SCC 
and 30% ADC. 
Two neo-
adjuvant cycles 
of cisplatin and 
5- fluorouracil 
and 45 Gy 
radiotherapy. 
No difference in overall survival but 
increased rate of postoperative 
mortality of 11.1% nCRT vs. 3.4% 
SA, p=0.049. 
 
1.6.8 Neoadjuvant chemotherapy vs. neoadjuvant chemoradiotherapy 
followed by resection 
Previous to our study two randomized controlled trials have been performed comparing 
nCRT to nCT. Both have a limited sample size and it is still unclear which treatment strategy 
to recommend. Several studies have, in indirect comparisons, shown a higher rate of 
complete histological response and R0 resections and a slightly better long-term outcome for 
patients who receive nCRT compared to nCT (102, 176, 177). Neoadjuvant radiotherapy in 
addition to chemotherapy increases local tumor control but some studies also show an 
increased risk of postoperative complications, especially heart and lung problems possibly 
due to the distribution of the radiation field. nCRT might give a higher risk of postoperative 
complications in patients with squamous cell carcinomas than adenocarcinomas (68, 128). 
The interpretations of these analyses are uncertain due to the heterogeneous design of the 
included studies and in particular due to the fact that the studies that have compared nCRT to 
nCT have a limited sample size (178). 
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Table 3. Randomized clinical trials comparing nCT to nCRT. 
Study Patients Oncological treatment Results 
Stahl (117) 
J Clin 
Oncology 
2009. 
126 patients with 
ADC were 
randomized to 
nCRT (n=60) or 
nCT (n=59). 
Two and a half courses of 
cisplatin, fluorouracil, and 
leucovorin in the nCRT 
group two courses with 
the addition of 30 Gy 
concurrent radiotherapy, 
2 Gy fractions. 
Three-year survival rate was 47.4% 
in the nCRT group vs.27.7% in the 
nCT group, p=0.07, HR for death in 
the nCRT group was 0.67 (95% CI, 
0.41 to 1.07). Postoperative 
mortality was increased in the 
nCRT group; 10.2% v 3.8% p=0.26. 
Burmeister 
(128) 
Eur J Cancer 
2011. 
75 patients with 
ADC randomized 
to nCRT (n=39) 
or nCT (n=36). 
Two neoadjuvant cycles 
of cisplatin and 5- 
fluorouracil. In the nCRT 
group with the addition of 
concurrent radiotherapy 
of 35 Gy 2.3 Gy fractions. 
No difference in overall survival but 
increased rate of histological 
response 31% vs 8%, p=0.01, and 
R0 resection 100% vs. 89%, 
p=0.04. 
 
1.6.9 Meta-analyses of nCRT and nCT 
Meta-analyses of nCRT and nCT for esophageal cancer have shown survival benefits for both 
treatments with slightly better outcomes for patients receiving nCRT (102, 107, 179-182). 
The improved outcome was seen for both AC and SCC and the anticipated increased risk for 
perioperative mortality was not shown. There was however heterogeneity in the included 
trials concerning tumor type, tumor location, chemotherapy and radiotherapy regimens and 
preoperative staging. 
Our group performed a meta-analysis investigating postoperative morbidity and perioperative 
mortality after nCRT, nCT and SA (68). The analysis included 23 trials, 7 compared nCT to 
SA, and 11 compared nCRT to SA. The analysis did not show any increased risk for 
postoperative complication, cardiac complication, respiratory complication, anastomotic 
leakage, 30-day mortality, total postoperative mortality or treatment-related mortality after 
nCT compared directly with SA. For patients with SCC, there was a statistically non-
significant trend of an increased risk of respiratory complications after nCT compared to SA 
(RR 1.46, 95 per cent CI 0.92 – 2.30, p=0.105). 
 nCRT did not increase the overall postoperative risk compared to SA, but patients with SCC 
did have a statistically significant increased risk of total postoperative mortality; risk ratio: 
1.95 (95% CI 1.06-3.60, p=0.032). Treatment related mortality was also increased in this 
group; risk ratio: 1.97 (95% CI 1.07-3.64, p=0.030). This was not seen for patients with AC. 
Direct comparison of nCT and nCRT did not show any significant difference.  
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Figure 3. Forest plots from the meta-analysis (68). 
  
Forest plot displaying the risk ratios for any postoperative complication after nCT compared 
to SA. NAC is an abbreviation for nCT. 
 
Any complication comparing nCRT and SA. NACR is an abbreviation for nCRT. 
 
Risk ratios for any complication after nCRT compared to nCT.   
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Total treatment-related mortality after nCT vs. SA. 
 
Total treatment-related mortality comparing nCRT and SA. 
 
Direct comparison of treatment-related mortality after nCRT and nCT. 
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2 AIMS 
The aims of this thesis were: 
To increase the knowledge about morbidity and mortality after neoadjuvant chemotherapy 
and chemoradiotherapy followed by esophagectomy. 
To compare the tumor regression grade after neoadjuvant chemotherapy compared to 
neoadjuvant chemoradiotherapy in a randomized controlled trial. 
To evaluate if neoadjuvant chemoradiotherapy increases the chance for overall survival 
compared to chemotherapy. 
To examine the effects of the implemented neoadjuvant treatment strategies in Sweden using 
population-based registry data. 
To estimate the magnitude of radiation exposure at the predicted site of the anastomosis in the 
gastric fundus. 
To investigate the effect of neoadjuvant chemoradiotherapy on the frequency, and severity of 
cervical anastomotic complications.  
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3 SUBJECTS AND METHODS 
3.1 THE NEORES TRIAL 
Papers I and III are based on the Neoadjuvant Chemotherapy versus Chemoradiotherapy in 
Resectable Cancer of the Esophagus and Gastric Cardia (NeoRes) trial, which was performed 
in Norway and Sweden during the period 2006–2013. The purpose of the trial was to clarify 
if neoadjuvant chemoradiotherapy gives a higher degree of complete histological response 
than neoadjuvant chemotherapy in patients undergoing treatment for cancer of the esophagus 
or gastro-esophageal junction. 
3.1.1 Setting 
Participating centers in Norway were the Oslo University Hospital, St Olav’s University 
Hospital, Trondheim, and Haukeland University Hospital, Bergen; and in Sweden, the 
Norrland University Hospital, Umeå, Karlstad Central Hospital, Örebro University Hospital, 
Sahlgrenska University Hospital, Göteborg, Mälarsjukhuset, Eskilstuna, and Karolinska 
University Hospital, Stockholm. 
3.1.2 Eligibility 
Patients with histologically confirmed SCC or AC of the esophagus or GEJ (including 
Siewert types I and II (183)) who were eligible for curative treatment with surgical resection 
were enrolled. Cervical cancers were required to be resectable without laryngectomy. Study 
participants had to be no more than 75 years of age, fit for esophagectomy, and have an 
Eastern Cooperative Oncology Group (ECOG) performance score (184) of 0 or 1. Adequate 
renal function defined as having normal serum creatinine levels and/or calculated glomerular 
filtration rate > 60 ml/min. Adequate haematological values: WBC >3x10
9
/litre, and platelets 
>100x10
9
/litre. Using the Union for International Cancer Control (UICC) TNM-6, patients 
with T1–3, any N (with the exception of T1N0) without evidence of distant metastases, were 
eligible (185-187). Comorbidities in the form of significant heart disease within the last year 
or a concurrent malignancy within the last five years constituted grounds for exclusion. 
3.1.3 Staging 
The clinical tumor and lymph node stage was assessed by upper gastrointestinal endoscopy 
and by a CT of the upper abdomen and chest. The use of FDG-PET and endoscopic 
ultrasonography was optional. 
3.1.4 Study design and Statistical analysis 
The study was designed as a phase-II randomized clinical trial comparing two neoadjuvant 
treatment regimens with complete histological response in the surgical specimen as the 
primary endpoint variable. The sample-size calculation was based on the intention of 
showing a difference in complete histological response of 15% between treatment arms with 
a power of 80%, which required 172 patients. 
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3.1.5 Randomization and masking 
Patients were stratified by histological tumor type and randomized independently through the 
use of computerized software at the Regional Oncological Center in Stockholm. The 
allocation sequence was concealed to all investigators. 
3.1.6 Ethics 
All patients signed a written informed-consent form. The study was approved by the 
Research Ethics Committees in Sweden, (registration numbers 2006/738-32 and 2008-403-
32), and Norway (Helseregion Midt-Norge registration number 4.2008.416). The full study 
protocol was registered in the Clinical Trials Database (https://clinicaltrials.gov; registration 
number NCT01362127). 
3.1.7 Chemotherapy 
Treatment had to be started within two weeks of randomization. Three cycles of cisplatin, 
100 mg/m
2
 day 1 and fluorouracil 750 mg/m
2
/24 hours, day 1-5 were given. Each cycle lasted 
21 days. In case of hearing impairment, tinnitus or deterioration of renal function cisplatin 
was replaced by carboplatin, AUC 5 (patients with squamous cell carcinoma) or oxaliplatin, 
130 mg/m
2
 (patients with adenocarcinoma). 
3.1.8 Radiotherapy 
In patients randomized to receive chemoradiotherapy 40 Gy was given (2 Gy once daily in 20 
fractions, 5 days a week) with a photon beam linear accelerator concomitant with 
chemotherapy cycle 2 and 3. A three-dimensional dose planning system was used. For tumors 
located mainly above the carina, the caudal border of the CTV was 5 cm below the tumor and 
the supraclavicular nodes defined the upper border. For tumors located mainly below the 
carina the cranial border of the CTV was 5 cm cranial to the tumor and the lower border was 
defined by the coeliac lymph nodes. In the lateral, anterior and posterior directions the CTV 
should embrace the gross tumor volume and para-esophageal area with a margin of 1 cm, 
although respecting anatomical barriers such as pleura, pericardium and bone. The planning 
target volume was carried out according to local routines. The dose to the lungs exceeding 20 
Gy was kept as low as possible not exceeding 1/3 of the lung volume. The volume of the 
heart that received ≥30 Gy was kept to a minimum. 
3.1.9 Surgery 
Patients were scheduled to undergo resection four to six weeks after having completed 
neoadjuvant treatment. The protocol required two-field lymphadenectomy, and the 
recommended procedure was esophagectomy with intrathoracic anastomosis through a 
laparotomy and a right-sided thoracotomy (Ivor Lewis procedure). A three-stage resection, 
with a right-sided thoracotomy, laparotomy, and cervical incision (McKeown procedure) was 
recommended for tumors in the middle and upper thirds of the esophagus. Other procedures 
were accepted in cases where the individual surgeon considered it appropriate, such as 
transhiatal esophagectomy, only employing laparotomy and a cervical incision for distal 
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esophageal and junctional cancers, or total gastrectomy for junctional tumors classified as 
Siewert type II (Table 1). 
3.1.10 Monitoring 
During the neoadjuvant therapy, patients were reviewed at least every third week. During 
radiotherapy patients were reviewed weekly. Adverse events were scored according to the 
NCI CTCAE v. 3.0 scale. Follow-up examinations were conducted every three months for 
the first two years after surgery and then every six months thereafter. During follow-up, 
radiological examinations were performed on suspicion of recurrence. 
3.1.11 Definitions of outcomes 
The primary endpoint was histological complete response in the primary tumor. Secondary 
endpoints were overall survival (time from randomization to death by any cause), 
progression-free survival, site of recurrence, R0 resection rate, number of lymph-node 
metastases, and toxicity of treatment. Progression was defined as a locoregional or distant 
recurrence, death from any cause, or disseminated disease before surgery. Patients with 
macroscopically unresectable tumors at surgery were regarded as having progression at the 
time of surgery. Patients with microscopic residual tumors (R1) were regarded as having 
progressed when there were clinical signs of disease progression. The resection was 
considered to be radical (R0) if there were no tumor cells within 1 mm of any resection 
margin (34, 188). Both longitudinal and circumferential resections margins were assessed. 
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3.2 PAPER I 
3.2.1 Study design 
Short-term follow-up of the first 90 days after surgery in the randomized clinical trial NeoRes 
was performed to compare the incidence and severity of postoperative complications after 
esophagectomy for carcinoma of the esophagus or GEJ.  
3.2.2 Definitions of outcomes 
Detailed data about perioperative complications and interventions during the whole length of 
stay were collected in the case record forms.  
Anastomotic leakage was assessed using CT scans with an oral water-soluble contrast 
medium, and any uncertainty was followed up with an endoscopy for confirmation.  
Surgical complications were defined as complications directly caused by the surgery, for 
example anastomotic leakage, conduit necrosis, bleeding, chylothorax, and recurrent 
laryngeal nerve paralysis.  
Nonsurgical complications included cardiovascular events and arrhythmias requiring 
treatment, thromboembolism, respiratory failure, and infections not related to the operation 
field.  
Clavien-Dindo Score: The severity of complications was classified according to the Clavien-
Dindo (CD) scoring system for postoperative complications. CD grade I is a complication not 
requiring any medical treatment. CD grade II requires pharmaceutical treatment or blood 
transfusion. CD grade IIIa requires surgical, endoscopic, or radiological intervention without 
general anesthesia, for example insertion of a drain or gastroscopy. CD grade IIIb requires 
intervention in general anesthesia, for example re-operation. CD grade IVa is defined as a 
life-threatening complication leading to single-organ dysfunction. CD grade IVb is defined as 
a life-threatening complication with multi-organ dysfunction. CD V is death of a patient 
caused by a complication of the treatment (66, 189, 190). The comprehensive complication 
index (CCI) including all postoperative complications giving patients an index between 0-100 
was also used (191).  
3.2.3 Statistical analysis 
Data were analysed according to the intention-to-treat principle. Comparisons between the 
two groups were done with the Chi-square test and Fisher’s exact test. Logistic regression 
was used to compare various complication rates between the two groups, while controlling 
for potential confounding effects of covariates (age, gender, WHO performance grade, T-
stage, tumor location). STATA/IC 13.1 software (StataCorp. LP, College Station, Texas, 
USA) was used for all statistical analyses.  
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3.3 PAPER II 
3.3.1 Study design 
The study was designed as a retrospective cohort study of all patients with cancer of the 
esophagus or gastro-esophageal junction undergoing esophagectomy operations and 
reconstructed with a gastric pull-up and cervical anastomosis at the Karolinska University 
Hospital in Stockholm 2007-2014. The aims of this study were first to estimate the magnitude 
of radiation exposure at the predicted site of the anastomosis in the gastric fundus, induced by 
nCRT within a standardized protocol, and secondly to assess whether nCRT affected the 
incidence or severity of cervical anastomotic complications. A non-irradiated group (non-RT) 
including patients with nCT and SA was compared to an irradiated group who had received 
nCRT. All esophagectomies with neck anastomosis were extracted from the hospital surgical 
planning system, ORBIT, and cross-matched for validation with data on all esophageal 
operations at the hospital from the electronic patient chart system TakeCare. Data regarding 
surgical procedures, neoadjuvant therapy, and potential confounding variables as well as 
outcomes were manually extracted from the patient charts in TakeCare. Comorbidity was 
calculated using the Charlson Comorbidity Index (192).  
3.3.2 Neoadjuvant treatment  
Radiotherapy (RT) was administered to target volumes defined in agreement with ICRU 
Report 50. All planning was to be carried out with a CT-based three-dimensional planning 
system with inhomogeneity correction. Patients were positioned for treatment according to 
tattooed marks on the skin and radiological landmarks in the vertebral column. The intended 
standard treatment dose was 40 Gy total to the tumor, given in 2 Gy fractions, 5 days/week 
over 4 weeks. GTV was defined as primary esophageal tumor and gross lymph node 
metastases. CTV included GTV and local subclinical disease. For tumors located at or above 
the level of the carina, the caudal border of CTV was 5 cm below diagnosed tumor and the 
supraclavicular nodes defined the cranial border. For tumors located mainly below the carina 
level, the cranial border of CTV included 5 cm of radiographically uninvolved esophagus and 
the coeliac lymph nodes defining the caudal border down to upper part of L1, while the 
coeliac lymph nodes were included in the target volume, at the same time defining the caudal 
border, down to the upper part of L1. In lateral, anterior and posterior directions, CTV should 
encompass GTV and para-esophageal area with a margin of 1 cm, but not including 
anatomical barriers such as pleura, pericardium or bone. Appropriate margins were added to 
the CTV to take into account the effects of organ and patient movements and inaccuracies in 
beam and patient set-up in order to ensure that the prescribed dose is actually absorbed in the 
CTV. All patients were followed weekly during radiotherapy.  
3.3.3 Radiation exposure assessment 
Detailed anatomical data on dose planning of radiation were extracted directly from the dose 
plan in the Varian treatment planning system (Eclipse, Varian Medical Systems, Palo Alto, 
CA, USA) for irradiated patients. For each of these patients, two esophageal surgeons (FK 
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and MN) blinded to patient identity and outcome, estimated the likely site of cervical 
anastomosis on the fundus part of the stomach corresponding to the future gastric conduit, 
using the dose planning CT. The planned radiation dose to this site was recorded for each 
patient.  
3.3.4 Surgery 
In most patients operated on for esophageal or junctional carcinoma at the Karolinska 
University Hospital during the study period, an Ivor Lewis procedure with an intrathoracic 
anastomosis was used. The patients included in the study, comprising only the proportion in 
which a cervical anastomosis was employed, were operated on with other approaches due to 
tumor factors, such as location and stage, and patient factors such as comorbidity, age and 
previous surgery. Transhiatal esophagectomy was used primarily in junctional cancers in 
patients with severe, especially pulmonary, comorbidity. Open three-field McKeown 
esophagectomy was used mainly in tumors located in the mid and upper esophagus. 
Minimally invasive techniques, three-stage laparoscopic and thoracoscopic, as well as the 
hybrid approaches combining laparotomy, thoracoscopy and neck incision or laparoscopy, 
thoracotomy, and neck incision, were used during the last years of the study period due to the 
shift to minimally invasive techniques implemented at the department. Before the conduit 
was created, the right gastric artery was identified and the branches of the artery to the distal 
part of the antrum were preserved. A gastric tube about 4 cm wide along the major curvature 
side of the stomach was completed by using a linear stapler applied along the contralateral 
side. The anastomotic technique was standardized and was the same in all the surgical 
approaches using cervical anastomosis where each anastomosis was constructed by use of 
interrupted monofilament, absorbable, single layer, 4-0 sutures end to side against a 
longitudinal incision of the greater curvature of the gastric conduit. 
3.3.5 Definitions of outcomes 
Postoperative outcome was registered during the full length of stay after surgery and during 
any readmission due to postoperative complications. 
Anastomotic complications: The occurrence of an anastomotic complication was defined as 
anastomotic leakage or gastric conduit necrosis diagnosed by CT with intraluminal contrast 
medium, endoscopy, or both. 
Surgical complications: Surgical complications were defined as all complications directly 
related to the surgical field, including anastomotic complications, surgical site infections, 
thoracic duct injury, postoperative hemorrhage and recurrent laryngeal nerve paralysis. 
Nonsurgical complications: Nonsurgical complications comprised cardiovascular events and 
arrhythmias requiring treatment, thromboembolism, respiratory failure requiring invasive or 
non-invasive intervention, and serious infections not related to the surgical field such as 
sepsis and pneumonia.  
Overall postoperative morbidity: The overall postoperative morbidity included both surgical 
and non-surgical complications. 
Severity of complications: The severity of the anastomotic complications was classified using 
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the Clavien-Dindo score (189). 
Ninety-day mortality: The 90-day mortality was defined as death by any cause within 90 days 
after the esophagectomy. 
Length of hospital stay: The length of in-hospital stay was defined as the time in days from 
the esophagectomy to discharge. 
3.3.6 Statistical analysis 
Comparisons between the two groups were made using Student’s t-test for means, and 
Fisher’s exact test or Chi-square tests for binomial outcomes. Multivariable logistic 
regression was performed for anastomotic leakage leading to Clavien-Dindo score IVa or 
worse. Confounding variables that were used in the multi-variable model were age, sex, ASA 
score (193, 194), smoking status, clinical T-stage and N-stage, tumor location, surgical 
approach, Charlson Comorbidity Index (192, 195), and alcohol abuse. STATA/IC 13.1 
software (StataCorp. LP, College Station, Texas, USA) was used for all statistical analyses. 
3.3.7 Ethics 
Approval was granted from the regional research ethics committee of Stockholm (reg. no. 
2014/1093-31/1). 
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3.4 PAPER III 
3.4.1 Study design 
Analysis of the primary outcome; complete histological regression, and three year follow-up 
of overall survival and disease-free survival in the NeoRes trial was performed. 
3.4.2 Definitions of outcomes 
All surgical specimens were reviewed by an expert pathologist at the Karolinska University 
Hospital in Stockholm, who was blinded to the randomization outcome of each individual 
patient.  
The tumor regression grade was defined according to Chirieac (124) as the quota of tumor 
cells and fibrosis and was assessed on a four-grade scale. TRG 1 represents histological 
complete response; TRG 2 represents 1–10% remaining tumor cells; TRG 3, 11–50% tumor 
cells; and TRG 4, > 50% tumor cells. Case-record forms and patient files were reviewed, 
particularly with regard to evidence of disease progression or of recurrence, and in the case of 
death during the first three years of follow-up; the cause of death was also carefully assessed. 
Survival was calculated from the day of inclusion until death of any cause during the first 
three years. 
3.4.3 Statistical analysis 
Data were primarily analysed according to the intention-to-treat principle in all randomized 
patients. Per protocol was also performed where the patients were defined as those who had 
received three cycles of neoadjuvant chemotherapy and, in the nCRT group; 40 Gy 
radiotherapy, in accordance with the study protocol. Comparisons between the groups were 
done with the Chi-square test and Fisher’s exact test. The Cox proportional hazard model and 
the log rank test were used. The significance level was set at 5%. Subgroup analyses by sex, 
age, ECOG performance score, histological tumor type, tumor location, clinical T-stage, and 
N-stage were prespecified. STATA/IC 13.1 software (StataCorp. LP, College Station, Texas, 
USA) was used for all statistical analyses.  
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3.5 PAPER IV 
3.5.1 Study design 
A cohort study population was collected between 1
st
 January 2006 and 31
st
 March 2014 using 
the prospectively registered exposure and outcome data retrieved from nationwide, 
population-based registers crossed-matched by personal registration (social security) numbers 
assigned to all Swedish residents. All patients who underwent esophagectomy with curative 
intent due to cancer in the esophagus or GEJ including Siewert types I and II were included in 
the study. Inclusion tumor stage was T1-T4 with any N stage, with the exception of T1N0. 
Potential confounding baseline variables including tumor characteristics, age, sex, ASA score 
and Karnofsky performance score, were compiled. Postoperative morbidity was reported in 
the registry as surgical or non-surgical complications.   
3.5.2 The Swedish National Register for Esophageal and Gastric Cancer 
(NREV) 
The register was started in 2006, and since then more than 95% of all patients with 
esophageal or gastric cancers diagnosed in Sweden have been registered. A validation study 
has shown the accuracy of the data in the registry to be 94% (196). Data are reported to the 
central register in an online data form by the physician who is responsible for treating the 
patients at each individual time point. The first form is reported at the time of the diagnosis, 
the second at surgery, the third at the first postoperative follow-up, and the fourth at one year 
after diagnosis or upon death. Data are monitored by the six Regional Cancer Centers and 
regular follow-ups are performed in order to complete the register. Death dates were retrieved 
from the Swedish population register (197).  
3.5.3 Exposure 
The neoadjuvant chemotherapy regimens in Sweden are specified in guidelines written by the 
regional cancer centers. During the study period, patients with adenocarcinomas received 
either three cycles of cisplatin 100 mg/m
2
 d and 5-fluorouracil 750 mg/m
2
/24 hours, or 
perioperative administration of epirubicin 50 mg/m
2
, cisplatin 60 mg/m
2
 and fluorouracil 200 
mg/m
2
/24 hours, according to the MAGIC regimen (103). Squamous cell carcinomas were 
treated with three cycles of cisplatin 100 mg/m
2
 d and 5-fluorouracil 750 mg/m
2
/24 hours. 
The standard neoadjuvant radiotherapy was delivered in 2 Gy fractions for a total dose of 40 
Gy (198). Patients were divided into three groups according to registered preoperative 
treatment strategy: SA, nCT, and nCRT. 
3.5.4 Definitions of outcomes 
All reported complications were included in the analysis. The Clavien-Dindo score for 
severity grade of complications was included in the register from January 2012 onwards, but 
contained too few patients to allow for a meaningful analysis. Postoperative complications 
were divided into surgical and non-surgical complications. The definitions of outcomes used 
in the register were applied in the study: 
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Surgical complications included anastomotic leakage (defined as assessed with CT scan with 
an oral water-soluble contrast medium, and any uncertainty was followed up with 
endoscopy), conduit necrosis, bleeding, chylothorax, or recurrent laryngeal nerve paralysis.  
Bleeding was defined as a blood loss of more than 2 litres or requiring surgical re-
intervention.  
Conduit necrosis was defined as clinically significant ischemia with perforation or ulcer. 
Abdominal or thoracic abscess was reported when radiologically or surgically verified with a 
size of at least 3x3 cm.  
Significant lymph leakage was defined when drainage was required for more than 7 days or 
surgical re-intervention was needed.  
Recurrent laryngeal nerve paralysis was diagnosed by an otolaryngologist.  
Non-surgical complications included cardiovascular complications, respiratory failure, 
pneumonia, and infections not related to the operation field.  
Pneumonia was defined by chest x-ray findings and fever, cough and/or dyspnoea. 
Septicemia was defined as body temperature above 38.3 C (101 F) or below 36 C (96.8 F), 
and a positive blood culture.  
Cardiovascular complications included cardiac arrhythmias requiring medical treatment, 
myocardial infarction, and cerebral embolism.  
Pulmonary embolism was defined as radiologically confirmed emboli requiring treatment. 
Survival was calculated from the date of the diagnosis until death or censoring on 9
th
 April 
2014. 
3.5.5 Statistical analysis 
The associations between neoadjuvant treatment and postoperative complications, mortality 
and long-term survival were investigated. Multivariable logistic regression modelling, the 
Chi-square test and Fischer´s exact test were used for binomial outcomes. The Cox 
proportional hazard model was used for the survival analyses. A multivariable model tested 
various potential confounding variables: age, sex, ASA score I-IV (199), Karnofsky 
performance score (195) (0-100), cT stage, cN stage (186), histological tumor type, tumor 
location, year of treatment, and centre. The final model was designed through a stepwise 
simple testing of all relevant potential confounding factors. A propensity score was calculated 
using clinical T- and N-stage, tumor location, tumor type, sex, age, ASA-score, performance 
score. Regression analysis with covariate adjustment using the propensity score were 
performed and did not significantly differ from the Cox regression (data not shown). 
Analyses were performed using STATA
®
 version 13 software (StataCorp LP, College 
Station, Texas, USA). 
3.5.6 Ethics 
Approval was granted by the Regional Research Ethics Committee of Stockholm (registration 
nr: epn 2013/596-31/3). 
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4 RESULTS 
4.1 PAPER I 
4.1.1 Study enrolment and neoadjuvant treatment 
During the study period, 285 patients were screened for inclusion. Of these, 181 patients were 
randomized, 91 to nCT and 90 to nCRT (Figure 4). The median observation time after 
randomization was 57 months. Randomization resulted in a well-balanced distribution of 
baseline characteristics (Table 4). Seventy-four patients in the nCRT study arm (82%) 
received the planned 40 Gy radiotherapy dose, among those that did not receive the full 
radiotherapy the median dose was 27 Gy.  In the nCT study arm 78 patients (85%) received 
three cycles, while the corresponding number of patients in the nCRT arm was 67 (74%, 
p=0.06). In total, 98 severe adverse events (SAE) were registered, and of these, 41 (42%) 
occurred in the nCT group and 57 (58%) in the nCRT group (p=0.14). Three of these events 
were lethal. One patient died from neutropenia and septicaemia in the nCT arm, whereas two 
patients died in the nCRT arm: one from pulmonary embolism and the other from tumor 
occlusion of the trachea (Table 5). 
The median time between randomization and surgery was 92 days in the nCT arm and 97 
days in the nCRT arm. Of the 181 randomized patients, 160 (88%) came to surgery, and 156 
(86%) underwent esophagectomy. Subgroup analysis stratifying for tumor type showed a 
statistically significant difference in the resection rate for patients with SCC; 19 (76%) in the 
nCT group and 24 (96%) in the nCRT group (p=0.04). The corresponding figures for AC 
were 59 patients (89%) in the nCT group and 54 (83%) in the nCRT group (p=0.29).  
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Figure 4. Study enrollment in the NeoRes trial.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* The reasons for not being surgically explored were (i) SAEs (three in each treatment 
group), (ii) disease progression (six after nCT and three after nCRT), and (iii) general 
physical deterioration with or without the registration of SAEs (one patient after nCT and 
five after nCRT). Two patients in each treatment arm were found to have metastatic disease 
at surgery, and consequently resection was aborted. 
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Table 4. Characteristics of patients with cancer in the esophagus and gastro-esophageal 
junction according to allocated treatment. 
(%) nCT nCRT 
Age   
Median (range) 63 (37–75) 63 (38–74) 
Gender   
Female 14 (15) 18 (20) 
Male 77 (85) 72 (80) 
Tumor type   
Adenocarcinoma 66 (73) 65 (72) 
Squamous-cell carcinoma 25 (27) 25 (28) 
Tumor location
a
   
Proximal 2 (2) 2 (2) 
Middle 13 (14) 13 (14) 
Distal 59 (65) 61 (68) 
Gastro-esophageal junction 17 (19) 14 (16) 
Clinical T-stage
b
      
T1 1 (1) 1 (1) 
T2 31 (34) 31 (34) 
T3 59 (65) 58 (64) 
Clinical N-stage
b
   
N0 34 (37) 33 (37) 
N-positive 57 (63) 57 (63) 
ECOG performances status
c
    
ECOG 0 77 (85) 75 (83) 
ECOG 1 14 (15) 15 (17) 
Preoperative endoscopic ultrasound 63 (69) 65 (72) 
Preoperative FDG-PET 41 (45) 46 (51) 
Surgical approach   
Ivor Lewis esophagectomy 54 (69) 49 (63) 
Transhiatal esophagectomy 7 (9) 8 (10) 
Three-stage esophagectomy 16 (21) 19 (24) 
Total gastrectomy  1 (1) 2 (2) 
No resection 13 (14) 12 (13) 
Total 91 (50) 90 (50) 
a) Tumor location was assessed by endoscopy and computed tomography. b) Tumor stage 
(TNM) was assessed by endoscopy and computed tomography with optional use of 
endoscopic ultrasonography (EUS) and PET-CT. c) ECOG performance status score 0–5. 
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Table 5. Chemotherapy according to protocol, severe adverse events during neoadjuvant 
treatment and postoperative results according to randomization. 
(%) nCT nCRT p-value 
40 Gy neoadjuvant radiotherapy - 74 (85) - 
3 cycles of neoadjuvant chemotherapy 78 (86) 67 (74) 0.06 
Severe adverse events:        
Infection  5 5  
Nausea and vomiting 2 6  
Nutritional deficiency  13 13  
Gastrointestinal symptoms  1 5  
Cardiovascular event  7 14  
Renal failure  7 4  
Infection  5 5  
Neutropenia/thrombocytopenia  2 5  
Other  3 3  
Death*  1 2  
Total number SAE 41 57 0.14 
* In the nCRT group one patient died from pulmonary embolism and from occlusion of the 
trachea; in the nCT group one patient died due to neutropenia and septicaemia. 
4.1.2 Postoperative outcome 
There was no postoperative 30-day mortality in either group. Six (8%) patients in the nCRT 
group and two (3%) in the nCT group died within 90 days of surgery. The difference was not 
statistically significant (p=0.28). Of the two deaths after nCT one patient died because of 
postoperative respiratory failure, without any surgical complication, while the other died due 
to rapid tumor progression, without any serious postoperative complication. All five patients 
who died within 90 days after nCRT did so due to serious complications, although two also 
had signs of early tumor recurrence. Three of these patients had surgical complications, of 
which one had gastric conduit necrosis and two died in progressive respiratory failure (Table 
6). 
The total surgical complication rate was 38% (n = 29) in the nCRT group and 35% (n = 27) 
in the nCT group. The corresponding figures for nonsurgical complications were 31% (n = 
24) and 21% (n = 16). The proportion of patients suffering from any type of complication 
was 55% (n = 42) for nCRT and 45% (n = 35) for nCT (p=0.23). Data regarding individual 
and pooled complication types are shown in Table 6.    
Logistic regression analysis of surgical and non-surgical complications, as well as for severe 
complications (Clavien-Dindo IIIb or higher), with adjustment for age, gender, T-stage, 
tumor location and WHO classification grade, did not significantly differ from the univariate 
results, thus indicating a low risk of confounding owing to failure in randomization (data not 
shown). 
Thirty percent (n = 23) of the patients resected after nCRT experienced a complication that 
scored IIIb or higher in the Clavien-Dindo system, corresponding to reintervention in general 
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anesthesia, admission to intensive care for single or multiple organ failure, or death due to 
complication. The corresponding figure was 17% (n = 13) among patients operated on after 
nCT (p=0.05). The mean CCI was 41 in the nCRT group and 31 in the nCT group (p=0.03). 
The median Clavien-Dindo complication severity score among those with any complication 
was IIIb in the nCRT group (n = 42) and IIIa in the nCT group (n = 35). This difference was 
statistically significant (p=0.001). 
Table 6. Postoperative complications, mortality and Clavien-Dindo score. 
(%) nCRT nCT p-value 
30-day mortality 1 (1) 0 (0) 1.0  
90-day mortality 6 (8) 2 (3) 0.28 
Surgical complication
a
   29 (38) 27 (35) 0.69 
Non-surgical complication
b
  24 (31) 16 (21) 0.13 
Any complication
c
  42 (55) 35 (45) 0.23 
Anastomotic leakage
d
   10 (13) 7 (9) 0.45 
Respiratory complication
e
  17 (22) 10 (13) 0.14 
Cardiovascular complication
f
   7 (9) 4 (5) 0.37 
Clavien-Dindo score
g
     
I 1 (1) 3 (4)  
II 9 (12) 7 (9)  
IIIa 9 (12) 12 (15)  
IIIb 14 (18) 8 (10)  
Iva 4 (5) 4 (5)  
Ivb 0 (0) 0 (0)  
V 5 (6) 1 (1)  
Total: 42 (55) 35 (45)  
Clavien-Dindo score IIIb or higher 23 (30) 13 (17) 0.05 
Median Clavien-Dindo score IIIb IIIa 0.001 
Mean CCI 41 31 0.03 
a) Surgical complications—for example, anastomotic leakage, conduit necrosis, bleeding, 
chylothorax, and recurrent laryngeal nerve paralysis.  b) Nonsurgical complications—for 
example, cardiovascular complications including arrhythmias requiring treatment and 
thromboembolism, respiratory failure, and infections not related to the operation field.  
c) Patients suffering from either surgical or nonsurgical complications. d) Anastomotic 
leakage was assessed using CT scan with an oral water-soluble contrast medium, and any 
uncertainty was followed up with endoscopy. e) Respiratory complications include 
pneumonia, pleural effusion requiring postoperative placement of drains, and respiratory 
failure in general. f) Cardiovascular complications include cardiac arrhythmias requiring 
treatment, myocardial infarction, cerebral embolism, and pulmonary embolism. 
g) The severity of complications scored according to the Clavien-Dindo system and the 
Comprehensive Complication Index. 
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4.2 PAPER II 
4.2.1 Study sample and treatment 
Seventy consecutive patients who, due to cancer, underwent esophagectomy with cervical 
esophagogastrostomy were included in this analysis. The non-irradiated group (non-RT) 
consisted of 42 patients, 10 of whom received neoadjuvant chemotherapy without radiation, 
and 32 treated with esophagectomy alone. The irradiated, nCRT group, comprised 28 
patients. The Charlson comorbidity score was higher in the non-RT group but the difference 
was not statistically significant; ASA classification was similar in both groups. The mean age 
was higher in the non-RT group compared to the nCRT group, at 68 vs. 63 years (Table 7). 
The standard radiotherapy dose of 40 Gy was given to 25 patients, while two received 38 Gy, 
and one 50 Gy. The radiation dose plan assessment was performed on 22 of the 28 patients in 
the nCRT group. We were unable to retrieve dose planning data in six cases either due to 
software updates or because patients had received their radiotherapy at other hospitals. The 
analyses showed that 20 out of 22 patients (93%) were planned to be irradiated at the site of 
the future anastomosis in the gastric fundus. Between 15 - 100% of the full dose was planned 
to be delivered to the gastric fundus. The mean dose was 17.3 Gy, and the median dose was 
10.6 Gy (Figure 5). An example of a dose plan CT image is shown in Figure 6. 
4.2.2 Anastomotic complications 
In total there were 28 anastomotic complications in the 70 patients (40%): in 16 of the 42 
non-RT patients (38%) and in 12 of the 28 nCRT patients (43%, p=0.69). Among the patients 
in the non-RT group who received neoadjuvant chemotherapy, there were 3 (30%) cases of 
anastomotic complications.  
Among the patients in the nCRT group, the anastomotic complications were classified as 
Clavien-Dindo grade IVa or higher, indicating a complication demanding ICU care for single 
organ failure or worse, in 11 of 28 patients (39%) compared to in 7 of 42 (17%) in the non-
RT group (p=0.03). In the nCRT group, 3 patients (11%) died due to anastomotic compli-
cations compared to none in the non-RT group (p=0.06, Table 8 and Figure 7). The crude 
odds ratio for a Clavien-Dindo grade IVa or worse in the nCRT group was 3.2 (95% CI: 1.1-
9.8, p=0.038), and adjusted for the Charlson Comorbidity Index and T-stage, the odds ratio 
increased to 6.0 (95% CI: 1.52 -23.50, p=0.021) when compared to the non-RT group.  
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Table 7. Patient characteristics, tumor data and surgical approaches. 
(%) Non-RT nCRT p-value 
Surgery alone  32 (76) 0 (0)  
Neoadjuvant chemotherapy nCT 10 (24) 0 (0)  
Neoadjuvant chemoradiotherapy nCRT 0 (0) 28 (100)  
Female  15 (36) 4 (14) 0.048 
Male  27 (64) 24 (86)  
Age (SD) 71 (11.6) 64 (9.5) 0.016 
Smoking 28 (67) 24 (86) 0.10 
Alcohol abuse
a
 7 (17) 5 (18) 0.90 
WHO performance status
b 
   0.46 
WHO 0 36 (86) 26 (93) - 
WHO 1 6 (14) 2 (7) - 
ASA score    <0.001 
I 18 (43) 16 (57)  
II 15 (36) 8 (29)  
III 9 (21) 4 (14)  
Charlson Comorbidity Index
c   0.34 
0 23 (55) 19 (68)  
1 11 (26) 7 (25)  
2 8 (19) 2 (7)  
Adenocarcinoma 22 (52) 17 (61) 0.71 
Squamous cell carcinoma 17 (40) 10 (36)  
Other 3 (7) 1 (4)  
Tumor location
d
:   0.78 
Proximal  1 (2) 2 (7)  
Middle  11 (26) 7 (25)  
Distal  19 (45) 11 (39)  
GEJ 11 (26) 8 (29)  
T-stage
e
:   0.06 
I   9 (21) 0 (0)  
II  8 (19) 5 (18)  
III 22 (53) 21 (75)  
IV  3 (7) 2 (7)  
N-stage
f
:   0.39 
N0 23 (55) 12 (55)  
N1 12 (29) 9 (41)  
N2  2 (5) 1 (5)  
Missing  5 (12) 0 (0)  
Surgical approach
g
:   0.031 
Transhiatal esophagectomy   17 (40) 3 (11)  
Minimally invasive esophagectomy 12 (29) 12 (43)  
Three-field esophagectomy  10 (24) 7 (25)  
Thoracoscopic hybrid esophagectomy  3 (7) 6 (21)  
a) Alcohol abuse was defined as an overconsumption leading to clear clinical consequences 
b) WHO performance status score 0–5. c) Charlson comorbidity index at baseline.(192). d) 
Tumor location by endoscopy and computed tomography. e) T stage by endoscopy and CT 
with optional use of endoscopic ultrasonography (EUS) and PET-CT. f) Clinical n stage by  
endoscopic ultrasound or FDG-PET-CT. g) All procedures included a cervical anastomosis. 
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Table 8. Postoperative outcome. 
(%) non-RT nCRT p-value 
30-day mortality  0 (0) 2 (7) 0.08 
90-day mortality  3 (7) 4 (14) 0.33 
Length of stay, median days 25 19 0.41 
Surgical complication
a
  25 (60) 14 (50) 0.43 
Non-surgical complication
b
  37 (88) 23 (82) 0.49 
Any complication
c
  39 (93) 23 (82) 0.25 
Pneumonia 18 (43) 16 (57) 0.24 
Respiratory insufficiency  16 (38) 14 (50) 0.32 
Cardiovascular complication
d
  14 (33) 4 (14) 0.10 
Postoperative ICU care, median days 11 17 0.42 
Esophageal stricture 20 (48) 8 (29) 0.29 
Anastomotic complication
e
   16 (38) 12 (43) 0.69 
Clavien-Dindo score for anastomotic complication
f
  
I 0 (0) 0 (0) - 
II 1 (2) 0 (0) - 
IIIa 2 (5) 1 (4) - 
IIIb 6 (14) 0 (0) - 
IVa 5 (12) 4 (14) - 
IVb 2 (5) 4 (14) - 
V 0 (0) 3 (11) - 
Total: 16 (38) 12 (43) - 
Median Clavien-Dindo score IIIb IVb 0.002 
a) Surgical complications—for example, anastomotic leakage, conduit necrosis, bleeding, 
chylothorax, and recurrent laryngeal nerve paralysis. b) Nonsurgical complications—for 
example, cardiovascular complications including arrhythmias requiring treatment and 
thromboembolism, respiratory failure, and infections not related to the operation field. c) 
Patients suffering from either surgical or nonsurgical complications. d) Cardiovascular 
complications include cardiac arrhythmias requiring treatment, myocardial infarction, 
cerebral embolism, and pulmonary embolism. e) Anastomotic complication was assessed 
using CT scan with an oral water-soluble contrast medium, and any uncertainty was followed 
up with endoscopy. f) The severity of complications was scored according to the Clavien-
Dindo system for classifying surgical complications. 
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Figure 5. Radiation exposures at the planned site of anastomosis in the nCRT group. 
 
 
The estimated dose to the site of the future gastroesophageal anastomosis in the 22 analyzed 
patients. Mean dose was 17.3 Gy (95% CI 11.3 - 23.3), and median dose was 10.6 Gy.  
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Figure 6. Computerized tomography image showing radiation dose planning. 
 
Figure 7. Distribution of Clavien-Dindo grade after anastomotic complication. 
 
Box plots of the distribution of Clavien-Dindo scores after anastomotic complications in the 
two groups. The median score was IIIb in the non-RT group, and IVb in the nCRT group 
(p=0.002).  
Primary tumor in the 
gastroesophageal junction and 
targeted lymph nodes delineated 
with red lines. Full dose of 40 Gy 
area in light red color, 
surrounding partially irradiated 
area in yellow, green and blue. 
The future site of anastomosis in 
the gastric fundus is within the 
partial radiation target area.  
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4.3 PAPER III 
4.3.1 Pathological evaluation and 3-year survival 
Histological complete response was achieved in 7 (9%) of the patients in the nCT arm, versus 
22 (28%) in the nCRT arm (p=0.002). Of the patients with histological complete response, 26 
(90%) did not have any metastatic lymph nodes, while three patients (10%), all treated with 
nCRT, had at least one metastatic lymph node. A median of 22 lymph nodes was found in 
patient specimens after nCT, compared to 16 after nCRT (p=0.003). Of patients resected in 
the nCT arm, 48 (62%) had lymph-node metastases, versus 27 (35%) in the nCRT arm 
(p=0.001). R0 resection was achieved in 58 (74%) patients in the nCT arm, versus 68 (87%) 
in the nCRT arm (p=0.04, Table 9). 
Three-year overall survival rate using intention-to-treat analysis was 49% in the nCT arm, 
and 47% in the nCRT arm (p=0.77). The crude hazard ratio (HR) for death during the first 
three years after randomization was, in the nCRT arm, 1.09 (95% CI 0.73–1.64), compared to 
the nCT arm, and the corresponding HR adjusted for sex, age, ECOG performance status, 
histological type, clinical T-stage, and N-stage was 1.11 (95% CI 0.74–1.67). The crude HR 
for patients with AC in the nCRT arm was 1.22 (95% CI 0.76–1.94), and the adjusted HR 
was 1.11 (95% CI 0.74–1.67). For patients with SCC in the nCRT arm, the crude HR was 
0.83 (95% CI 0.37–1.89), and the adjusted HR was 0.52 (0.20–1.36). Per protocol analyses of 
overall survival stratified by histological tumor type indicated similar numbers with lower 
survival in patients with AC after nCRT and slightly improved survival for patients with SCC 
after nCRT. These differences did not reach statistical significance. Patients who responded 
to the neoadjuvant treatment with TRG 1 or 2 had a three-year survival rate of 74%, 
compared with 46% for TRG 3 or 4 (p=0.001), HR =0.40 (95% CI 0.23–0.73, Figure 8). 
The progression-free three-year survival rate was 44% in both treatment arms. Among 
patients with AC, 41% exhibited progression-free three-year survival in the nCT arm, and 
40% in the nCRT arm did the same. The corresponding figures for the patients with SCC 
were 52% in the nCT arm and 56% in the nCRT arm (Figure 9). For data on incidence of 
local and distant recurrence see Table 9. 
Analysis of the causes of death by follow-up year revealed significantly more deaths in the 
first year after randomisation related to causes other than tumor recurrence; these were, in 
effect, SAEs during neoadjuvant therapy and postoperative complications: in the nCRT arm, 
11 of 24 patients (46%) experienced such events, and in the nCT arm, 3 of 20 (15%) did 
(p=0.04, Figure 10). 
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Table 9. Outcome of treatment according to allocated neoadjuvant therapy and subgroup 
analysis of adenocarcinoma and squamous-cell carcinoma. 
  
(%) nCT nCRT p-value 
Tumor regression grade
a
*   <0.001 
1: Histological complete response 7 (9) 22 (28) 0.002 
2: 1–10% tumor cells 5 (6) 19 (24)  
3: 11–50% tumor cells 5 (6) 14 (18)  
4: >50% tumor cells  61 (78) 23 (29)  
Surgical resection** 78 (86) 78 (87) 0.85 
R0 resection
c
* 58 (74) 68 (87) 0.04 
Tumor-free longitudinal margin* 75 (96) 77 (99) 0.31 
Tumor-free circumferential margin* 60 (78) 69 (88) 0.09 
Lymph-node metastasis* 48 (62) 27 (35) 0.001 
Three-year overall survival** 45 (49) 42 (47) 0.77 
Progression-free 3-year survival
b**
 40 (44) 40 (44) 0.95 
Length of hospital stay (median days) 16 19 0.29 
Recurrent disease* 35 (45) 28 (36) 0.25 
Local recurrence* 15 (19) 13 (16) 0.68 
Outcome of treatment in patients with AC 
Tumor regression grade
a
*   <0.001 
1: Histological complete response 4 (7) 12 (22)  
2: 1–10% tumor cells  3 (5) 15 (28)  
3: 11–50% tumor cells 4 (6) 10 (19)  
4: >50% tumor cells  48 (81) 17 (31)  
Surgical resection** 59 (89) 54 (83) 0.29 
R0 resection
c
* 58 (74) 68 (87) 0.04 
Lymph-node metastasis* 38 (64) 21 (39) 0.007 
Recurrent disease* 31 (53) 20 (37) 0.10 
Local recurrence* 13 (22) 9 (16) 0.44 
Three-year survival** 32 (48) 28 (43) 0.54 
Progression-free three-year survival
b
** 27 (41) 26 (40) 0.92 
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*= percent of resected patients, ** = percent of total, a) The TRG was defined as the quota of 
tumor cells and fibrosis and was assessed on a four-grade scale. TRG 1: no tumor cells; TRG 
2: 1–10% tumor cells; TRG 3: 11–50% tumor cells: and TRG 4: >50% tumor cells (11).  
b) Progression was defined as local or distant recurrence, death from any cause, and 
disseminated disease before or at surgery.  c) The resection was considered R0 if there were 
no tumor cells within 1 mm of any resection margin. 
  
Outcome of treatment in patients with SCC 
Tumor regression grade
a
*   0.04 
1: Histological complete response 3 (16) 10 (42)  
2: 1–10% tumor cells 2 (11) 4 (17)  
3: 11–50% tumor cells 1 (5) 4 (17)  
4: >50% tumor cells 13 (68) 6 (25)  
Surgical resection** 19 (76) 24 (96) 0.04 
R0 resection
c
* 16 (84) 20 (83) 0.94 
Lymph-node metastasis* 10 (53) 6 (25) 0.06 
Recurrent disease* 4 (21) 8 (33) 0.37 
Local recurrence* 2 (10) 4 (17) 0.52 
Three-year survival** 13 (52) 14 (56) 0.78 
Progression-free three-year survival
a
** 13 (52) 14 (56) 0.78 
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Figure 8. Kaplan-Meier plots of overall three-year survival according to treatment group, 
tumor regression grade, tumor type, and per protocol analysis.  
 
 
  
a) Estimated three-year 
survival of 181 patients with 
esophageal and gastro-
esophageal junctional cancer, 
randomized to neoadjuvant 
chemotherapy or neoadjuvant 
chemoradiotherapy followed 
by surgery. Intention-to-treat 
analysis: crude hazard ratio 
for death in the nCRT group 
was 1.09 (0.73–1.64), HR 
adjusted for sex, age, ECOG 
performance status, 
histological type, clinical T-
stage, and N-stage: 1.11 (0.74–
1.67). 
 
b) Kaplan-Meier plot 
showing the estimated 
survival according to 
response to the neoadjuvant 
therapy (11). Patients with 
TRG 1 or 2 have a three-year 
survival rate of 74%, versus 
46% for the patients with 
TRG 3 or 4 (p=0.001), HR 
=0.40 (95% CI 0.23–0.73). 
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c) The crude hazard 
ratio in intention-to-
treat analysis for 
patients with AC and 
nCRT was 1.22 (0.76–
1.94), adjusted for sex, 
age, ECOG 
performance status, 
histological type, 
clinical T-stage, and N-
stage: 1.20 (0.75–1.92). 
 
d) Patients with SCC 
and nCRT had in an 
intention-to-treat 
analysis HR =0.83 
(0.37–1.89), adjusted 
for sex, age, ECOG 
performance status, 
histological type, 
clinical T-stage, and N-
stage: 0.52 (0.20–
1.36). 
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e) Per protocol analyses of overall survival stratified by histological tumor type 
showing a trend for decreased survival for patients with AC after nCRT; crude HR 
1.31 (95% CI 0.76–2.26) and a trend towards improved survival after nCRT for SCC 
patients: crude HR 0.90 (95% CI 0.34–2.38) compared to nCT. 
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Figure 9. Progression-free survival subgroup analysis.
 
Forest plot showing univariate hazard ratios for death or progression with 95% confidence 
intervals, according to baseline characteristics. Hazard ratios adjusted for baseline 
covariates are displayed under the multivariate HR caption. 
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Figure 10. Causes of death during years 1–3 after randomization, according to treatment 
group. 
 
Analysis of the causes of death by follow-up year showed that during the first year after 
randomization, 11 of 24 (46%) in the nCRT arm and 3 of 20 (15%) in the nCT arm (p=0.04) 
died of causes other than tumor recurrence—that is, of severe adverse events during 
neoadjuvant therapy and postoperative complications. 
4.4 PAPER IV 
4.4.1 Study sample 
In total, 1020 patients with esophageal or gastric cardia cancer type I and II underwent 
esophagectomy with curative intent, whereof neoadjuvant treatment was given to 521 (51%), 
and 499 (49%) were treated with SA. nCT was used for 205 (20%) patients and nCRT for 
316 (31%). SA was more frequently practiced in the first years of the study period, while the 
use of nCT and nCRT increased over time. No patients were lost to follow-up and the median 
follow-up times were 5 years in the SA group, 3 years for nCT and 4 years in the nCRT 
group. Transthoracic open esophagectomy with the Ivor Lewis technique was the most 
commonly used surgical technique (Table 10). The overall 30- and 90-day mortalities were 
1.7% and 5.4%, respectively. Anastomotic leakage occurred in 6.9% of the patients (Table 
11). The overall five-year survival rate was 34.2% (Table 12). ) The SA group had missing 
data concerning ASA-score in 10% and performance score in 13% of the cases, compared to 
2-4% in the neoadjuvant treatment groups (Table 10). 
4.4.2 Surgery alone vs. neoadjuvant chemotherapy 
 There were some differences between patients treated with SA and those who received nCT 
regarding baseline characteristics (Table 10). The patients in the SA group were older, had a 
lower average Karnofsky performance score and a higher ASA score. Tumor-specific 
characteristics also differed, with more advanced tumor stages and a higher frequency of 
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clinical N positive disease in the nCT group. The adjusted odds ratio for surgical 
complications in the nCT group was 2.71 (95% CI: 1.55-4.72) (Table 11). There was no 
difference between these groups concerning non-surgical complications, postoperative 
mortality, or R0 resection rates. The frequency of lymph node metastases was lower in those 
given nCT (p=0.013) (Table 12).  
A Cox proportional hazards model showed a statistically significant improved overall 
survival for patients with squamous cell carcinomas after nCT, with adjusted HR: 0.39 (95% 
CI: 0.17-0.87) . For patients with adenocarcinoma, there was no significant difference in 
overall survival for the whole cohort, with adjusted HR: 0.93 (95% CI: 0.64-1.36), (Table 13, 
Figure 11). Stratified analysis, including only fit patients without comorbidity (Karnofsky 
performance status 100 and ASA score I), showed a strong trend for an advantage in overall 
survival after nCT, with an adjusted HR: 0.47 (95% CI: 0.21-1.04), compared to patients 
treated with SA (Table 13). 
4.4.3 Surgery alone vs. neoadjuvant chemoradiotherapy 
Baseline characteristics differed between the groups with older age, higher ASA score and 
lower Karnofsky performance score in the SA group. Histological tumor type and tumor 
locations were similar, but clinical T stage and clinical N stage were more advanced in the 
nCRT group (Table 10). The adjusted odds ratio for postoperative surgical complication in 
the nCRT group was 1.32 (95% CI: 0.84-2.10), suggesting a slightly increased risk, not 
reaching statistical significance however. The adjusted odds ratio for postoperative mortality 
within 90 days of surgery in the nCRT group was 2.37 (95% CI: 1.06-5.29) (Table 11). R0 
resection rate was significantly higher after nCRT (P<0.001), and the risk for lymph node 
metastases was lower (P<0.001) (Table 12).  
A trend towards improved overall survival after nCRT was observed in patients with 
squamous cell carcinomas, 54% 5-year survival compared to 30% after SA (p=0.066) 
adjusted HR: 0.74 (95% CI: 0.47-1.18) (Table 12, Table 13, Figure 8) and in stratified 
analysis including only fit patients without comorbidity hazard ratio point estimates dropped 
substantially with a significant survival advantage for nCRT compared to SA, adjusted HR 
0.15 (95% CI: 0.04-0.59). There was no advantage in overall survival for patients with 
adenocarcinoma (Table 12, Table 13, and Figure 11).  
4.4.4 Neoadjuvant chemotherapy vs. neoadjuvant chemoradiotherapy 
The study groups were similar concerning age, gender and performance status. Proportions of 
histological tumor type differed between the treatment groups; 79 (25%) of the patients in the 
nCRT group were SCC, while only 19 (9%) of patients treated with nCT were SCC. Tumor 
location differed between groups as did clinical T stages, with more advanced stages in the 
nCRT group (p=0.001) (Table 10). In the nCRT group, 23 (7%) patients died within 90 days 
of surgery compared to 10 (5%) in the nCT group (p=0.27). Postoperative complications 
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were reported with similar frequency except those concerning septicaemia, which occurred in 
5 (2%) patients after nCT and 20 (6%) patients after nCRT (p=0.04) (Table 11).  
In patients with squamous cell carcinomas, there was no difference in number of identified 
lymph nodes or lymph node metastases between the nCT and nCRT groups. The R0 resection 
rate was significantly higher after nCRT (p=0.009). Pathological T stage was T2 in both 
groups, and the rates of histological complete response were similar (Table 12). There was no 
difference in long-term overall survival between the two groups (Table 13, Figure 11). 
Concerning adenocarcinomas, the average number of lymph nodes found in the surgical 
specimen was 22 after nCT and 15 after nCRT (P<0.001). Lymph node metastases were 
found in 103 (61%) of the patients in the nCT group and in 83 (45%) of the patients in the 
nCRT group (p=0.003); the corresponding figures for R0 resection rates were 145 (86%) and 
175 (95%), respectively (p=0.005). Median pathological tumor stage after nCT was T3. In the 
nCRT group the median pathological tumor stage was T2 (P<0.001). Histological complete 
response was achieved in 8 (4%) patients after nCT, and in significantly more, 40, patients 
after nCRT (17%, p<0.001) (Table 12). There was no statistically significant difference in 
survival between patients treated with nCT and nCRT (Table 13, and Figure 11). 
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Table 10. Characteristics of patients with cancer in the esophagus or gastro-esophageal 
junction, by preoperative treatment. 
 SA nCT nCRT SA 
/nCT 
SA/ 
nCRT 
nCT/ 
nCRT 
n (%)    p-value 
Total 499 (49) 205 (20) 316 (31) - - - 
Median follow-up 
time (months) 
63 38 49 
<0.001 <0.001 0.004 
Year of treatment 
(median) 
2009 2011 2010    
Age, median (SD) 70 (9.8) 63 (7.9) 63 (10.0) <0.001 <0.001 1.0 
Gender    0.009 0.002 0.98 
Female 123 (25) 32 (16) 49 (16)    
Male 376 (75) 173 (84) 267 (84)    
Performance status
a
     0.010 0.063 0.50 
100 220 (51) 127 (63) 176 (58)    
80 182 (42) 69 (34) 117 (39)    
60 30 (7) 5 (2) 10 (3)    
40 1 (0) 0 (0) 0 (0)    
Missing data 66  4  13    
ASA score
b    0.010 <0.001 0.058 
I 124 (28) 69 (34) 131 (43)    
II 220 (49) 107 (53) 149 (49)    
III 99 (22) 26 (13) 24 (8)    
IV 6 (1) 0 (0) 0 (0)    
Missing data  50 3 12    
Histological tumor type <0.001 0.24 <0.001 
Adenocarcinoma 338 (68) 182 (89) 229 (73)    
Squamous cell 
carcinoma 136 (28) 19 (9) 79 (25) 
   
Other 20 (4) 4 (2) 7 (2)    
Tumor location
c
     0.002 0.36 0.001 
Proximal 16 (3) 1 (0)  8 (3)    
Middle 71 (15) 12 (7) 44 (15)    
Distal 230 (50) 96 (53) 169 (56)    
GEJ 146 (32) 73 (40) 81 (27)    
Missing data 36 23 14    
Clinical T stage
d
     0.023 <0.001 0.001 
T1 4 (1) 0 (0) 0 (0)    
T2 191 (48) 70 (41) 69 (24)    
T3 199 (50) 96 (56) 206 (72)    
T4 2 (1) 5 (3) 10 (4)    
Missing data 103  34 31    
Clinical N stage
e
     0.008 <0.001 0.65 
N0 273 (55) 100 (50) 143 (45)    
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N1 162 (32) 88 (44) 151 (48)    
N2 9 (2) 11 (6) 15 (5)    
N3 1 (0) 0 (0) 0 (0)    
NX 54 (11) 6 (3) 7 (2)    
Surgical approach    0.13 0.014 0.039 
Transthoracic 
esophagectomy 
391 (90) 178 (92) 271 (94)    
Transhiatal 
esophagectomy 
26 (6) 4 (2) 7 (2)    
Minimally invasive 
technique* 
8 (2) 4 (2) 10 (3)    
Gastrectomy   9 (2) 7 (4) 1 (0)    
Missing data   65 12 27    
a) Karnofsky performance score 0–100. b) American Society of Anesthesiologists physical 
status classification. c) Tumor location was assessed by endoscopy and computed 
tomography. d) Tumor stage (TNM) was assessed by endoscopy and computed tomography 
with optional use of endoscopic ultrasonography (EUS) and PET-CT. e) Clinical N stage was 
assessed by means of endoscopic ultrasound or FDG-PET-CT. *The code for minimally 
invasive esophagectomy was introduced in Sweden in 2014. Before that time, all procedures 
were classified as open surgery. 
Table 11. Postoperative morbidity and mortality after esophagectomy due to cancer in the 
esophagus or gastro-esophageal junction, by preoperative treatment. 
 SA nCT nCRT SA/ 
nCT 
SA/ 
nCRT 
nCT/ 
nCRT 
 (%)    p-value  
30-day mortality 9 (2) 3 (1) 5 (2) 1.0 1.0 1.0 
90-day mortality 22 (4) 10 (5) 23 (7) 0.79 0.081 0.27 
Surgical complication
a
  100 (20) 61 (30) 82 (26) 0.005 0.048 0.34 
Anastomotic leakage
b
   29 (6) 18 (9) 23 (7) 0.15 0.40 0.53 
Bleeding
c
  7 (1) 6 (3) 5 (2) 0.22 1.0 0.36 
Conduit necrosis
d
 10 (2) 6 (3) 9 (3) 0.42 0.48 1.0 
Intra-abdominal abscess
e
 5 (1) 2 (1) 4 (1) 1.0 0.74 1.0 
Intrathoracic abscess
e
 3 (1) 8 (4) 9 (3) 0.003 0.014 0.51 
Severe lymph leakage
f
  7 (1) 10 (5) 12 (4) 0.006 0.027 0.55 
Recurrent nerve paralysis
g
 16 (3) 5 (2) 14 (4) 0.81 0.45 0.34 
Other serious surgical 
complication 
37 (7) 18 (9) 30 (9) 0.54 0.29 0.78 
Non-surgical complication
h
  119 (24) 57 (28) 75 (24) 0.27 0.97 0.30 
Pneumonia
i
   36 (7) 21 (10) 23 (7) 0.18 0.97 0.23 
Septicaemia
a
  19 (4) 5 (2) 20 (6) 0.36 0.010 0.042 
Cardiovascular complication
k
   30 (6) 5 (2) 13 (4) 0.048 0.24 0.31 
Pulmonary embolism
l
  7 (1) 6 (3) 8 (3) 0.17 0.24 0.79 
Other non-surgical serious 
complication 
54 (11) 28 (14) 33 (10) 0.29 0.87 0.27 
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Logistic regression of complications and postoperative mortality. 
 SA nCT SA nCRT nCT nCRT 
Non-surgical complications                                  Odds ratio (95% CI): 
Crude 1.0 1.23 (0.85-1.78) 1.0 0.99 (0.71-1.38) 1.0 0.81 (0.54-1.21) 
Adjusted* 1.0 1.32 (0.82-2.12) 1.0 0.94 (0.59-1.48) 1.0 0.62 (0.38-1.01) 
Surgical complications 
Crude 1.0 1.69 (1.17-2.45) 1.0 1.40 (1.00-1.95) 1.0 0.83 (0.56-1.22) 
Adjusted* 1.0 2.01 (1.24-3.25) 1.0 1.32 (0.84-2.10) 1.0 0.77 (0.48-1.22) 
Anastomotic leakage 
Crude 1.0 1.56 (0.85-2.88) 1.0 1.27 (0.72-2.24) 1.0 0.82 (0.43-1.55) 
Adjusted* 1.0 1.81 (0.82-3.96) 1.0 1.22 (0.59-2.50) 1.0 1.01 (0.48-2.11) 
90-day mortality 
Crude 1.0 1.11 (0.52-2.39) 1.0 1.70 (0.93-3.11) 1.0 1.53 (0.71-3.29) 
Adjusted** 1.0 1.52 (0.58-4.01) 1.0 2.37 (1.06-5.29) 1.0 1.37 (0.57-3.29) 
 
a) Including anastomotic leakage, conduit necrosis, bleeding, abscess, chylothorax, recurrent 
laryngeal nerve paralysis, or other serious surgical complication. b) Anastomotic leakage 
was defined as a leakage diagnosed using CT scan with an oral water-soluble contrast 
medium, and any uncertainty was followed up with endoscopy. c)Bleeding more than 2 litres 
or need for surgical intervention. d) Clinically significant ischemia with perforation or ulcer. 
e) Radiologically or surgically verified abscess at least 3x3 cm. f)Lymph leakage requiring 
drainage for more than 7 days or surgical intervention. g) Diagnosed by an otolaryngologist. 
h) Non-surgical complications include cardiovascular complications, pneumonia, 
septicaemia, pulmonary embolism or other serious non-surgical complication. i) Pneumonia 
by chest x-ray findings, and fever, cough or dyspnoea. j) Body temperature above 101 F (38.3 
C) or below 96.8 F (36 C), and a positive blood culture. k) Cardiovascular complications 
include cardiac arrhythmias requiring treatment, myocardial infarction, cerebral embolism, 
and pulmonary embolism. l) Radiologically confirmed emboli requiring treatment. 
*Adjusted for age, ASA score, histological tumor type, tumor location, and center. 
**Adjusted for age, ASA score, Karnofsky performance score, histological tumor type, and 
center. 
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Table 12. Pathological results and long-term survival of patients after esophagectomy due to 
cancer in the esophagus or gastro-esophageal junction, stratified by histological tumor type 
and preoperative treatment. 
 SA nCT nCRT SA/ 
nCT 
SA/ 
nCRT 
nCT/ 
nCRT 
Adenocarcinomas       
                                                                                               n (%*)                                         p-value 
Number of resected lymph 
nodes, mean 
23 22 15 0.24 <0.001 <0.00
1 
Lymph node metastases 211 (72) 103 (61) 83 (45) 0.013 <0.001 0.003 
R0 resection rate 246 (83) 145 (86) 175 (95) 0.49 <0.001 0.005 
Tumor-free longitudinal 
margin 
287 (97) 158 (93) 183 (99) 0.12 0.12 0.007 
Tumor-free circumferential 
margin 
252 (86) 153 (91) 176 (95) 0.13 0.001 0.09 
Pathological T stage 
(median) pT3 pT3 pT2 1.0 <0.001 
<0.00
1 
Histological complete 
response - 8 (4) 40 (17) - - 
<0.00
1 
1-year survival 242 (77) 136 (83) 177 (82) 0.10 0.14 0.78 
3-year survival 115 (45) 47 (49) 63 (43) 0.48 0.67 0.33 
5-year survival 56 (31) 16 (35) 29 (33) 0.63 0.81 0.80 
Squamous cell carcinomas       
Number of resected lymph 
nodes, mean 24 17 14 0.072 <0.001 0.22 
Lymph node metastases 71 (62) 6 (33) 19 (30) 0.021 <0.001 0.77 
R0 resection rate 95 (82) 15 (83) 63 (98) 0.88 0.001 0.009 
Tumor-free longitudinal 
margin 107 (92) 18 (100) 64 (100) 0.22 0.022 1.0 
Tumor-free circumferential 
margin 103 (89) 15 (83) 63 (98) 0.51 0.021 0.009 
Pathological T stage 
(median) pT3 pT2 pT2 0.009 <0.001 1.0 
Histological complete 
response - 4 (21) 19 (24) - - 0.78 
1-year survival 94 (72) 16 (89) 60 (82) 0.13 0.11 0.49 
3-year survival 38 (37) 8 (62) 25 (48) 0.082 0.17 0.39 
5-year survival 24 (33) 3 (50) 14 (54) 0.41 0.066 0.87 
*=Percent of available patients for the stipulated analysis. 
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Table 13. Cox proportional hazard model of survival, by preoperative treatment, after 
esophagectomy in patients with cancer in the esophagus or gastro-esophageal junction, 
stratified by histological tumor type. 
 SA vs. nCT SA vs. nCRT nCT vs. nCRT 
Hazard ratio (95% CI) 
Adenocarcinomas 
Crude 1.0 0.75 (0.57-0.97) 1.0 0.99 (0.71-1.38) 1.0 1.19 (0.89-1.58) 
Adjusted* 1.0 0.93 (0.64-1.36) 1.0 1.07 (0.75-1.54) 1.0 1.13 (0.78-1.63) 
Squamous cell carcinomas 
Crude 1.0 0.44 (0.20-0.95) 1.0 0.66 (0.45-0.97) 1.0 1.49 (0.66-3.34) 
Adjusted** 1.0 0.39 (0.17-0.87) 1.0 0.74 (0.47-1.18) 1.0 1.55 (0.66-3.61) 
Patients with ASA 1 and Karnofsky performance score 100 
Adenocarcinomas 
 SA vs. nCT SA vs. nCRT nCT vs. nCRT 
Crude 1.0 0.70 (0.41-1.19) 1.0 1.00 (0.65-1.52) 1.0 1.43 (0.85-2.40) 
Adjusted* 1.0 0.47 (0.21-1.04) 1.0 0.78 (0.39-1.55) 1.0 1.63 (0.81-3.28) 
Squamous cell carcinomas 
Crude 1.0 0.46 (0.06-3.50) 1.0 0.54 (0.22-1.32) 1.0 1.21 (0.15-9.90) 
Adjusted** 1.0 0.09 (0.01-1.09) 1.0 0.15 (0.04-0.59) 1.0 3.33 (0.33-33.47) 
*Adjusted for age, sex, ASA score, cT stage, cN stage, year of treatment, and centre. 
**Adjusted for sex, ASA score, cN stage, year of treatment, and centre.  
 
  
 60 
Figure 11. Survival according to treatment group stratified by histological tumor type. 
 
Kaplan-Meier plot of overall survival, according to treatment, for patients who have 
undergone esophagectomy due to adenocarcinoma. SA vs. nCT: p=0.029, SA vs. nCRT: 
p=0.34, nCT vs. nCRT: p=0.24 (log rank test). 
 
Kaplan-Meier plot of overall survival, according to treatment, for patients who have 
undergone esophagectomy due to squamous cell carcinoma. SA vs. nCT: p=0.032, SA vs. 
nCRT: p=0.032, nCT vs. nCRT: p=0.93 (log rank test).  
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5 DISCUSSION 
5.1 METHODOLOGICAL DISCUSSION 
5.1.1 Internal validity and precision 
The quality of a study is determined by the internal validity and the precision. Internal 
validity depends on the level of systematic error, also called bias. The precision of a study 
reflects the degree to which repeated measures in unchanged conditions show the same 
results and indicates the impact of random error on the estimate. Random errors are 
impossible to exclude completely but if the sample size is adequate this problem will be 
controlled. The degree of random errors is statistically described in the p-values and 
confidence intervals of the estimates. Different study designs can increase the efficiency of 
the study and reduce the risk of bias. Systematic errors can be categorized in many different 
ways; I have used the three groups which are described below. When performing a study 
efforts are made to minimize each type of bias.   
5.1.2 Selection bias 
The idea of a clinical study is to investigate cause and effect of various factors. For 
example; patients with disease can be compared to healthy controls, or people who are 
exposed to a factor to people who are not exposed. In every study a selection of patients, a 
sample, from a source population needs to be made. This selection can potentially introduce 
bias. A selection bias occurs when the study population is selected based on factors 
associated with the exposure and outcome. The aim is to include a sample that is 
representative of the population in question. If patients are lost to follow-up in a study due 
to factors associated with the exposure and outcome this can introduce another type of 
selection bias. There are many different types of selection bias but all represent errors that 
occur as a result of the method of inclusion. 
5.1.3 Information bias 
In a scientific study large amounts of data are gathered. Some of the data will with most 
certainty be incorrect. This is also called misclassification. It can be caused by a human 
error, for instance typing 0 by mistake when the data point should be 1. This type of error is 
normally completely random and evenly distributed in the investigated groups. In this case 
it will typically not create a false association between exposure and outcome. This type of 
misclassification is called non-differential. If the non-differential error is large it will 
however hide or reduce and possibly conceal a true difference, so-called “bias towards the 
null”.  
Another information bias is the differential misclassification which occurs when the errors 
are made with an association to the outcome and the exposure. This can create a false 
association or hide a truth. Recall bias is a potentially differentiated misclassification, for 
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example patients with disease can have a higher tendency to remember being exposed 
compared to healthy controls leading to a potentially overestimated risk of the exposure. 
5.1.4 Confounding 
Confounding is a systematic error that can be difficult to deal with. It can be explained as a 
mixture of effects. A classic example is that alcohol consumption is associated with lung 
cancer; however, this association is explained by the increased frequency of smokers 
among people who drink alcohol; i.e. the association is not true but a confounding effect of 
smoking. A confounder must be associated both to the exposure and the outcome, and it 
should not be an intermediate in the causal pathway from the exposure to the outcome. 
Randomization, restriction and matching are three ways to minimize confounding. When 
calculating the estimate it is also possible to adjust for confounders in a multivariate 
regression model. Residual confounding is the remaining error in an analysis after 
adjustments have been made. This can be caused by misclassification of confounding 
variables, unknown confounders, or adjustment in too wide categories. Confounding by 
indication can occur in observational studies because a group with an exposure can be 
different compared to the unexposed group because of the indication for the exposure. For 
example patients with more advanced tumors will receive more aggressive treatment with 
surgery and chemotherapy compared to patients with less advanced disease.  
5.1.5 External validity 
If a study has few systematic errors, and high precision, it has a potentially a high external 
validity. The study has measured the effect of the exposure in the sample in a correct way, 
reflecting the effect of the exposure in the source population. A study with high validity can 
be generalized to the population from which the sample has been selected, the so called 
source population. If the sample in that case is also representative of a larger population, for 
example the population of a country, the study results can be generalized, and expected to 
apply to, that population. If a study only includes women it can have high internal and 
external validity but the results may not be generalized to men because they were not 
included in the source population. 
5.1.6 Case-control study 
When investigating an uncommon outcome it is effective to use a case control study design. 
A number of subjects with an outcome are compared to a group of controls without the 
outcome. It is possible to examine the importance of many factors in the development of 
the outcome in a case-control study. To minimize confounding the controls can be matched 
on one or more variables, for example; age and gender. The selection of cases and controls, 
ant the matching, is a potential source of bias. A case-control study performed within a 
defined cohort it is called a “nested case-control study”.  Case-control studies are relatively 
easy and cheap to perform, especially if the data is available. 
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5.1.7 Cohort study 
When the exposure is rare it is more effective to start with an exposed group and compare it 
to a representative group of unexposed study subjects in a so-called cohort study. The 
design can be retrospective or prospective. Advantages of a cohort study are that more than 
one exposure and outcome can be examined, and that there is no risk of recall bias. Large 
prospective cohort studies can examine the effects of implemented treatment on a 
population and also investigate the causes of a disease over a long time period. Famous 
examples are the Framingham Heart study and the Nurse´s Health study. 
5.1.8 Randomized controlled trial 
A RCT is basically a form of cohort study where the exposure is randomly assigned to the 
study participants. RCTs are now the gold standard in clinical research for evaluating 
treatment effects. The advantage is that, as long as the sample size is fairly large, the 
randomization will create two groups that will be very similar concerning known and 
unknown confounding variables. The idea is that the only difference between the groups 
should be the exposure in question. The internal validity in a well-performed RCT is 
normally of high quality. The generalizability depends on the internal validity, the precision, 
and the selected study population. Disadvantages with the RCTs are that they are resource 
demanding, expensive and time consuming. It can also be difficult to study other associations 
than the ones predetermined. The study design requires a situation where it is unknown which 
of two treatments has better outcomes. For ethical reasons it is not possible to investigate the 
effect of possibly harmful exposures and risks of disease with an RCT.    
5.1.9 Definitions of outcomes 
It is important that the reported outcomes of a study are clearly defined. Concerning survival 
this can vary in several different ways. Survival analyses in a study can encompass different 
events depending on the definition. For example if you include; death by any cause, death 
attributable to the disease in question, or death attributable to other causes in the analysis the 
results will differ. Today there are no standardized definitions of these comparative terms in 
survival analyses (200). This needs to be clearly described for the reader to be able to 
interpret the results correctly. The definitions of end-points concerning postoperative 
morbidity and mortality are even more difficult to standardize. The postoperative period can 
be defined as the period until the patient is discharged, the so-called “in-hospital” period, or 
the first 30 days, or 90 days after surgery. If a patient is readmitted to the hospital due to a 
complication of the surgery it should be defined as a postoperative complication but this is 
not always the case. There is also a risk that the patient is admitted to another clinic and the 
information about the complication might not be known to the researcher performing the 
study, leading to misclassification of the variable.  
Complications are defined and measured in many different ways. Information from a registry 
will in most cases include fewer events than a review of the patient´s chart performed by a 
dedicated investigator. The researcher can choose to include only serious complications or 
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count every small event that occurs in the postoperative period. Since there are no 
standardized definitions of postoperative complications it is important that the information 
about the applied definitions is stated in the report of the study. The Clavien-Dindo scoring 
system for severity of postoperative complications is a standardized system were the 
treatment or procedure following a complication is scored (66, 189-191). This system is 
validated in studies and enables researchers to compare the results of treatments in a more 
reliable way. It is also makes comparisons of different studies possible.  
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5.2 METHODOLOGICAL ASPECTS OF THE INCLUDED PAPERS 
Papers I and III are based on the NeoRes trial which is a multicenter RCT. The evidence 
grade from an RCT is today regarded as the highest possible. Of course the trial needs to have 
high external validity for the results to be generalizable to larger populations. Every patient 
who was diagnosed during the study period was assessed for inclusion in the trial which 
decreases the risk for selection bias. The study was monitored by an independent research 
nurse to minimize missing data and misclassifications. The trial was unfortunately paused for 
a period of two years for administrative reasons, which delayed the completion of the trial. 
We evaluated the possible effect on the outcome that overall improvements, that have been 
made in the care of the patients from 2006-2013, could have introduced. A sensitivity 
analysis comparing the patients in the first years of the trial to the last period did however not 
show any differences compared to the combined results, which indicates that the time of 
treatment did not affect the outcome in the trial.  
Paper II was a retrospective cohort study which in some aspects was challenging to analyse. 
The included groups were different at baseline concerning age, gender, ASA-score, and T-
stage. The analysis of the study was difficult because of the risk of bias caused by these 
variances. We chose to handle this by limiting our analysis to the risk for, and severity of, 
anastomotic complications. The overall survival, and the overall CD score, were also 
interesting but due to the risk of bias and residual confounding these results were uncertain 
and therefore not analysed. A multivariate adjusted regression analysis was designed through 
step-wise univariate with testing of all potential confounding factors. 
Paper IV has the strength of compiling a population-based cohort of more than 95% of all 
esophageal cancer patients in Sweden, thereby practically eliminating the risk of selection 
bias. A validation study has shown the data in the register to be highly accurate (196), 
indicating high external validity of the study. A down side of the registry-based study is that 
it is impossible to retrieve more information than that included in the registry. For example; 
detailed information about the neoadjuvant treatment concerning drugs and doses was 
unavailable. Further advantages with the design were the relatively large sample size, the 
complete follow-up concerning survival, and that practically all diagnosed patients, 
regardless of other characteristics, were included. This study effectively evaluates the effect 
of the implemented treatments on the Swedish population during these years. 
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5.3 GENERAL DISCUSSION 
5.3.1 Paper I: Postoperative outcome after neoadjuvant treatment  
In this work we were unable to detect any significant difference in the incidence of 
postoperative morbidity and mortality between the allocated treatments. However, 
complications were significantly more severe among patients who underwent resection after 
nCRT and there was a trend towards an increased incidence of respiratory and other 
nonsurgical complications in this group. 
There are several possible mechanisms by which nCRT may affect the risk and severity of 
postoperative complications. As suggested in two retrospective studies, chemoradiotherapy 
may induce an acute impairment of cardiac function, with a dose-dependent decrease in 
ventricular ejection fraction after different combinations of chemotherapeutic agents and 
radiation doses. (201, 202) Moreover, chemoradiotherapy has been reported to be associated 
with an increased NT-proBNP release, which is a well-known marker for global heart failure 
and a strong predictor of postoperative cardiac events. (203, 204) In an analysis performed 
within the NeoRes-trial our group found that nCRT but not nCT had a negative impact on 
systolic and diastolic ventricular function (205). Platins and 5-fluorouracil, that were used in 
the present trial, especially 5-fluorouracil, may also cause specific cardiotoxic side effects, 
including myocardial infarction (206). It has been shown that increased fraction dose 
increases the risk for pericardial effusions after nCRT (207).  In-depth knowledge of 
differences between nCT and nCRT regarding cardiotoxicity is, however, still largely 
lacking. 
The effects of radiotherapy on lung tissue are well studied, and the risk of radiation 
pneumonitis is strongly associated with the mean total lung dose (208, 209). Radiation 
pneumonitis is an acute inflammatory response to lung irradiation and can lead to lung 
fibrosis. (210) The volume of lung tissue, that is exposed to doses of 5 Gy or higher, has been 
associated with an increased risk of postoperative pulmonary complications (211). 
Chemotherapy combined with radiation to the lung has been shown to decrease lung function 
when the local radiation dose exceeds 13 Gy and increases the risk of radiation pneumonitis, 
possibly influenced by a synergism between radiation and chemotherapy effects. (212, 213) 
These and other factors may explain observations suggesting that patients’ preoperative 
working capacity, as assessed during bicycle ergometry, is impaired by preoperative 
chemoradiotherapy. (214) On the other hand, a variety of factors, such as patient compliance, 
anemia, and cardiac and respiratory function, may also influence the results of the ergometry. 
Taken as a whole, this body of data emphasizes the importance of further studies elucidating 
the mechanisms through which cardiopulmonary toxicity may be induced by 
chemoradiotherapy.  
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The postoperative 90-day mortality rate among the patients resected after neoadjuvant 
treatment reflects the magnitude of the surgical trauma elicited by esophagectomy; the figures 
are comparable to the levels reported in previous studies (87, 117). The difference in 90-day 
mortality between the treatment groups is not statistically significant; however, the numeric 
difference is still noteworthy and also accords with previous findings (68, 117). The overall 
complication rate in the present study is likewise similar to that reported elsewhere (68, 117).   
The two previous randomized trials of neoadjuvant chemoradiotherapy vs. chemotherapy; did 
not, using a limited sample size, detect any significant difference in postoperative morbidity 
or mortality. (117, 128) Despite this, the trial by Stahl et al. suggested an increased total 
postoperative mortality among irradiated patients similar to our experience (117).  
Both the median Clavien-Dindo score and the mean comprehensive complication index 
score, were significantly higher after nCRT than after nCT, indicating that the complications 
after nCRT, albeit not with certainty more frequent, are in fact more severe.  
There was a trend toward increased respiratory, cardiovascular, and total nonsurgical 
complications in the nCRT group. As the study was designed using complete histological 
response as the primary outcome variable, it is likely to be underpowered regarding the 
assessment of morbidity and mortality, making the absence of significant differences in 
postoperative morbidity and mortality between treatment arms possibly attributable to a type-
2 statistical error.  
In the most recently published randomized trial within the field, the CROSS trial, comparing 
nCRT with SA, the authors presented no indication of more complications or of increased 
mortality after esophagectomy and nCRT (87). The severity of complications was not 
reported in this trial. On the other hand, the recently published FFCD 9901 trial, which 
included only stage I–II esophageal cancer, but otherwise had a similar design to CROSS, 
showed a significant increase in postoperative mortality after chemoradiotherapy (118) 
compared to SA. Interestingly, this trial reported no difference in the overall frequency of 
postoperative complications, which was also the case in our trial. In the CROSS trial, the 
balance between adenocarcinomas and squamous cell cancers was 75% to 25%, whereas the 
relation was the opposite in FFCD 9901. Regarding surgical technique, this was not 
specifically reported in the CROSS trial, but the transhiatal approach was probably common, 
whereas the patients in FFCD 9901 underwent a transthoracic esophagectomy. In the present 
trial most patients underwent a transthoracic esophagectomy, and few were operated on using 
a transhiatal approach, which precluded a meaningful subgroup analysis regarding 
importance of the surgical approach. It is possible that nCRT may have a more severe effect 
on postoperative complications after transthoracic resection than those submitted to a 
transhiatal resection. Regarding the role of the histological subtype and the associated 
comorbidity profile, postoperative mortality may increase after neoadjuvant treatment 
predominantly in patients with squamous cell cancers, but not so in patients with 
adenocarcinomas, as suggested by our recently published meta-analysis (68). Owing to its 
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limited number of patients with squamous cell cancers, the present study could not address 
this hypothesis.  
5.3.2 Paper II: neoadjuvant chemoradiotherapy and cervical anastomosis 
In paper II we found that the vast majority of patients receiving nCRT before esophagectomy 
with cervical anastomosis were due to be irradiated at the site of the anastomosis in the 
gastric conduit. There was no difference in the incidence of anastomotic complications 
between the nCRT group and the non-RT group. However, when anastomotic complications 
occurred in the nCRT group, they were much more severe, with a manifold increased risk of 
organ failure requiring ICU care.  
The finding that preoperative radiation within a standard nCRT protocol included a 
significant radiation dose to the future gastric conduit and the site of the gastro-esophageal 
anastomosis raises serious concern and calls for improvement in the coordination of 
radiotherapy dose targeting and surgical approach. Another potential reason for inadvertent 
radiation of the future site of anastomosis is that patients generally are not required to be 
fasting, either before the dose planning imaging or during the radiotherapy treatment 
sessions. This may, depending on the degree of filling of the stomach, at each treatment 
session, cause variations in how much of the stomach wall is included in the radiation field.  
Our finding that nCRT is associated with significantly more severe cervical anastomotic 
complications, although the incidence is not increased, is consistent with other studies 
showing increased postoperative risk for patients undergoing nCRT compared to SA or to 
neoadjuvant chemotherapy alone followed by surgery (118, 215). There are also studies that 
do not show increased risk for postoperative morbidity and mortality after nCRT, but these 
studies do not present the severity of the complications (86, 87, 216, 217). None of the earlier 
studies focused on cervical anastomoses alone, and none of them showed such a large 
increase in the severity of complications after radiation as we observed in the present study.  
These findings raise the question of possible mechanisms for neoadjuvant nCRT to increase 
the severity of cervical anastomotic complications without clearly increasing the incidence. 
Evidence is accumulating to show that the addition of radiation therapy, in the given dose 
ranges, elicits discrete but defined impairments in both systolic and diastolic left ventricular 
function (205). Moreover the physical endurance of these patients may be compromised as 
well (214, 218), the consequences of which may well affect the resilience to otherwise 
manageable complications. Another, more speculative potential explanation could be that 
irradiation to the gastric fundus may cause anastomotic leaks by a partly different 
mechanism, compared to leaks unexposed to irradiation, perhaps with more influence of 
conduit necrosis.  
This study has several limitations. The small sample size limits the precision and prevents 
subanalyses. Moreover this is a retrospective observational study and accordingly there is a 
substantial risk of bias. On the other hand, the patients included comprised all 
esophagectomies performed due to cancer and reconstructed with a cervical anastomosis 
  69 
during the time period. The nCRT group and the non-RT group were not comparable as 
regards factors such as age and comorbidity. In fact, the non-irradiated patients were both 
older and had more comorbidity. These differences would normally act in such a way as to 
conceal a detrimental effect of radiation, but despite this, the nCRT patients in the unadjusted 
analyses had a threefold increased risk of organ failure due to anastomotic complications, 
compared to non-exposed patients. This difference was shown to even further increase after 
adjusting for the confounding factors as mentioned above.  
This study suggests that radiation, administered within a standard 40 Gy nCRT protocol, 
exposes the future anastomotic site of the gastric fundus to doses that may well impair 
healing of the subsequent cervical anastomosis Our data further suggest that nCRT may 
increase the clinical severity of anastomotic complications. Moreover, this study raises two 
important questions: 1. Do the findings regarding a substantial radiation targeting of the 
gastric fundus reflect broader clinical practice? 2. Does nCRT with partial radiation exposure 
of the future gastric conduit really cause cervical anastomotic complications of a more severe 
magnitude? These issues deserve serious scientific attention in large prospective studies.  
5.3.3 Paper III: neoadjuvant chemotherapy vs. chemoradiotherapy 
In this RCT, which compared nCT with nCRT treatments for esophageal and GEJ carcinoma, 
we have shown that nCRT significantly increases the proportion of complete histological 
response, increases the occurrence of N0 lymph-node status, and increases the R0 resection 
rate, but does so without a corresponding improvement in survival. Moreover, we have 
shown that patients who respond to the neoadjuvant treatment with tumor regression have 
significantly increased survival compared to patients without, or with a poor, response. 
Cisplatin and 5-fluorouracil still remain among the most well documented chemotherapeutic 
regimen choices in neoadjuvant chemotherapy and chemoradiotherapy for esophageal cancer 
(102, 128, 219, 220), although in recent years other alternatives have gained increasing 
popularity. In our present trial many patients had difficulty tolerating the full three cycles of 
chemotherapy in the nCRT arm and consequently only 74% completed three cycles, 
compared to 85% in the nCT arm. The number of cycles of platin-based chemotherapy 
needed for optimal anti-tumor effect has recently been studied in the British OE05 trial. In 
this trial Alderson et al showed that 4 cycles of epirubicin/cisplatin/capecitabine increased the 
tumor regression grade and that there were trends towards improved disease-free and 
progression-free survival for patients with gastro-esophageal adenocarcinomas compared to 2 
cycles of cisplatin and 5-FU. The toxicity was however increased and overall survival did not 
improve (156).  
This trial compared three cycles of neoadjuvant platin-5FU-based chemotherapy with a 
combined chemoradiotherapy regimen using the same chemotherapy but adding 40 Gy of 
radiotherapy. With some variations, both of these neoadjuvant therapy options have in recent 
decades been frequently used in clinical practice and in several trials (102, 171, 221) and both 
may be regarded as belonging to the standard neoadjuvant treatment options at the time this 
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trial started. These regimens have over the years undergone revisions, and in addition to the 
regimens used in this trial, the currently practiced adjunct therapy options in many Western 
countries are (i) neoadjuvant chemotherapy with two cycles of cisplatin and 5-fluorouracil in 
accordance with the OE02 trial (104, 220), (ii) perioperative chemotherapy modified after the 
MAGIC protocol (103), and (iii) chemoradiotherapy utilizing the CROSS trial regimen with 
chemotherapy, combining weekly paclitaxel and carboplatin with concomitant radiotherapy, 
totalling 41.4 Gy (87). Regarding the perioperative MAGIC type chemotherapy using 
epirubicin, oxaliplatin, and capecitabine/5-FU; although it may seem quite different from the 
nCT used in the present trial, it is clear that this therapy, especially for esophageal cancer 
patients, mainly rests on the neoadjuvant component because postoperative therapy can be 
administered to only about half of the patients. In the CROSS trial-chemoradiotherapy 
regimen, the radiotherapy is similar, while the chemotherapy is likely to have a lower 
systemic anti-tumor effect than the chemotherapy used in the present trial. 
The analysis in paper I showed that complications in this trial were significantly more severe 
after the addition of radiotherapy, and this is further supported by the analysis of the causes of 
death by follow-up year, which showed significantly more deaths unrelated to disease 
progression in the nCRT arm during the first year of follow-up. Several studies have shown 
that nCRT carries an increased risk of postoperative death compared to SA, a trend that has 
not been observed at all after nCT (68, 116, 118). Given the clearly superior complete 
histological response rate after nCRT compared to nCT, we surmise that the reason there is a 
lack of a corresponding advantage in overall survival may be that the combined impact of 
chemotherapy and radiotherapy takes a heavy toll by significantly increasing deaths by 
serious adverse events and complications during the first year of follow-up.  
Interestingly, the analysis of survival by histological tumor type revealed a trend towards 
improved survival after the addition of radiotherapy among patients with SCC and, 
conversely, a trend towards poorer survival with the addition of radiotherapy among patients 
with AC. The latter trend towards a survival disadvantage after the addition of radiotherapy in 
AC patients has to our knowledge not been described previously and, of course, given the 
lack of statistical significance, can be discussed only in a hypothesis-generating context. One 
reason for this difference in trends could be that the two previous studies comparing nCT and 
nCRT did not publish any per protocol survival data. Another reason may be that both these 
trials used a lower radiotherapy dosage, 30 and 35 Gy, respectively (117, 128). The toll of 
increased short-term non-cancer-related deaths in the nCRT arm affects patients with both 
histological tumor types; hence, the opposite survival trends for the two subtypes are puzzling 
but may be explained by the higher radiation sensitivity in SCC, leading to an overall 
beneficial effect of combination therapy in this histological type. 
Among the strengths of the study, it should be mentioned that the NeoRes trial is the largest 
randomized trial to date comparing neoadjuvant nCT and nCRT for resectable esophageal 
and GEJ cancer. The randomization was computerized and performed by an independent 
institution, stratifying for histological type. The two study groups were well balanced in the 
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distribution of age, gender, comorbidity, and tumor characteristics. Both the neoadjuvant 
therapy and surgical procedures were rigorously standardized in accordance with the 
protocol. No patients were lost to follow-up. A single expert pathologist, blinded to treatment 
allocation and outcomes, reviewed all surgical specimens. A limitation of the study is that it 
was designed to distinguish a difference in complete histological response and is hence 
underpowered for the survival analyses. The many early deaths not related to cancer 
progression in the nCRT arm illustrate the need for less toxic preoperative regimens with 
preserved efficacy.  
5.3.4 Paper IV: Population based data  
In paper IV we show that elderly patients, with more comorbidity but less advanced tumors, 
were more often treated with SA, than with bi- or trimodal therapy. The proportion of patients 
given neoadjuvant treatment continuously increased during the study period. Both types of 
neoadjuvant treatment seem to increase the risk for postoperative morbidity. Additionally 
both neoadjuvant regimens increase the overall survival in patients with squamous cell 
carcinomas, while patients with adenocarcinomas had no statistically significant benefit in 
overall survival after neoadjuvant treatment, although subgroup analysis including only fit 
patients without comorbidity showed a strong trend towards increased survival after treatment 
with nCT compared to SA. A small group of patients with SCC received nCT (n=19) with 
good results, but the limited sample size makes interpretations uncertain. 
The neoadjuvant chemotherapy regimens used in Sweden during the study period either 
comprised three preoperative cycles of platins and 5-FU or perioperative administration of 
three + three cycles of platins, 5-FU and epirubicin, according to the MAGIC protocol (103). 
These regimens use a higher total dose of chemotherapeutic agents compared to what has 
been used in most randomized clinical trials (103-105, 152, 161). These differences may well 
explain the increased frequency of surgical complications recorded after nCT in this study, 
contrary to what has previously been seen (68). We also found that nCRT increased the risk 
for postoperative mortality, which has previously been shown in some trials (68, 116, 118). 
The observational design of the study makes treatment selection with regard to disease 
severity a potential source of bias. Tumor stage and comorbidities have been included in the 
applied multivariate regression model in order to adjust for these differences. The missing 
data was slightly higher in the SA group concerning some baseline characteristics, which has 
been considered in the analysis through complete case analysis. 
In the setting of clinical trials patients are carefully selected for inclusion, while in this 
population-based study, all patients operated on with curative intention have been analysed. 
These patients are, as a group, likely to have more comorbidity and lower performance status 
than those selected for a trial. This may possibly explain the gap seen between the significant 
survival benefit in adenocarcinoma from both types of neoadjuvant therapy over SA in 
randomized trials compared to the findings in this observational study. A subgroup analysis 
of high performance status patients without comorbidities indicates an enhanced effect on 
survival of neoadjuvant treatment in this group; this, in a way, mimics the selection practiced 
 72 
in clinical trials, thus suggesting that outcome after neoadjuvant therapy might improve if 
patients were selected accordingly in clinical practice as well.  
Previous RCTs have used radiotherapy in a dose ranging from 18.5-45 Gy, most often 40 Gy, 
in combination with chemotherapy (86, 87, 116, 118, 158, 170-172). The RCTs that have 
compared nCRT to nCT showed increased tumor regression and R0 resection rates, but there 
is no detectable gain in survival compared to nCT (117, 128). The results from RCTs of 
neoadjuvant treatment and SA have displayed slightly improved survival and no increased 
risk for complications, which need re-evaluation in large prospective studies (68, 102). The 
results of our present study are consistent with previous trials with increased tumor 
regression, R0 resection rates, pathological node negative disease, and risk of treatment 
related mortality after nCRT, although with no difference in overall survival. The SA group 
displays a survival that is comparable to that after neoadjuvant treatments for 
adenocarcinomas in this cohort. The available evidence for an advantage from nCT and 
nCRT for patients with high age and severe comorbidity is weak. This could, perhaps 
together with some residual confounding from lower T- and N- stages, explain the relatively 
good results seen after SA in this study. Patients with adenocarcinoma treated with SA have a 
survival after multivariable adjustment for confounders similar to that of the patients that 
received neoadjuvant treatment and a likely benefit was only seen with nCT in patients with 
high performance status and without comorbidity. Regarding patients with squamous cell 
carcinoma this study confirms previous findings from Asia regarding a survival benefit with 
nCT (93) and Western evidence (87) regarding nCRT, albeit in this study again only 
statistically significant regarding high performance-low comorbidity patients. Further studies 
are needed to find a regimen with decreased risk of adverse events, and to define which 
groups benefit from nCRT. The ongoing trials Neo-AEGIS and Topgear, are comparing nCT 
and nCRT for esophageal and gastric cancer, and the results of these well-powered trials have 
the potential of changing standard practice (222, 223). Based on this study’s results, one can 
argue that nCT should be the treatment of choice for esophageal and GEJ adenocarcinomas. 
In this study fewer lymph nodes were examined by the pathologists after nCRT compared to 
nCT and SA, which is in line with previous studies showing that neoadjuvant chemo-
radiotherapy decreases the number of detected lymph nodes, malignant as well as benign (86, 
87, 117). A recent study has shown that the number of examined lymph nodes after nCRT 
was not a predictor of survival (224). nCRT increases the R0 resection rate and decreases 
lymph node metastases compared to SA and nCT without increasing survival for patients 
with adenocarcinomas. The reasons that this favourable tumor response did not translate into 
improved survival are still unclear and need to be addressed in future studies.   
The major strengths of this study are the nationwide, population-based design, covering more 
than 95% of all esophageal cancers diagnosed in Sweden, the complete follow-up, the 
prospectively collected data, and the large sample size. A limitation of this study is that it was 
not possible to validate postoperative complication data. Unfortunately, detailed information 
about the neoadjuvant treatments could not be found in the registry. Regarding postoperative 
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morbidities, completing the Clavien-Dindo score for severity of postoperative complications 
was not possible due to the fact that this classification was not introduced until quite recently. 
Patients were not randomized to the different treatment groups, which results in potential 
confounding; this was, however, dealt with in the multivariable analyses. There is always a 
risk for misclassification of both the exposures and the outcomes, but it is reasonable to 
assume that these are evenly distributed in the treatment groups (196). There were some 
missing data (cT stage, cN stage and tumor location), but in the multivariate adjusted models, 
complete case analysis was performed and no missing data affected the survival analyses. 
In conclusion, this large, nationwide prospectively-collected cohort study, which addressed 
the impact of neoadjuvant therapy as clinically practiced in an unselected, defined population, 
shows a survival benefit after both types of neoadjuvant treatment for patients with 
esophageal squamous cell carcinoma. An overall survival benefit was not seen for patients 
with adenocarcinomas. Neoadjuvant treatment was associated with an increased risk of 
postoperative morbidity and, after nCRT, even postoperative mortality. 
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6 CONCLUSIONS 
nCRT is not associated with a higher overall incidence of postoperative complications after 
esophagectomy than nCT.  
nCRT may increase the clinical severity of cervical anastomotic complications. 
The complications that occurred in patients who received nCRT were more severe than after 
nCT. 
There was statistically significant higher mortality, unrelated to cancer progression, in the 
nCRT group during the first year after diagnosis compared to nCT.  
Radiation, administered within a standard 40 Gy nCRT protocol, exposes the future 
anastomotic site of the gastric fundus to doses that may well impair healing of the subsequent 
cervical anastomosis.  
The addition of radiotherapy to neoadjuvant chemotherapy increases the complete 
histological response and R0 resection rates and decreases the proportion of patients with 
lymph node metastases.  
This thesis does not provide any evidence in support of using complete histological response 
as a surrogate marker for survival in the comparison of neoadjuvant therapies. 
Both nCT and nCRT improves survival for patients with esophageal squamous cell 
carcinomas compared to SA. 
An overall survival benefit of neoadjuvant treatment was not seen for patients with 
esophageal adenocarcinomas.  
Neoadjuvant treatment was associated with an increased risk of postoperative morbidity and, 
after nCRT, even postoperative mortality in an unselected population based cohort. 
In summary, this thesis shows that the use of nCRT as a standard treatment for esophageal 
and junctional adenocarcinomas may be questioned and that nCT could be a better 
alternative.  
Patients with esophageal SCC probably have an increased postoperative risk after nCRT 
compared to nCT but the gain in survival makes the treatment reasonable. Patient selection is 
likely very important in order to reach a positive outcome. 
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7 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Cancer i matstrupen (esofagus) är en tumörsjukdom som är förknippad med dålig prognos. 
Sjukdomen drabbar främst medelålders män men i vissa fall även yngre personer. Ungefär 
20% är kvinnor. Riskfaktorer för esofaguscancer är rökning, alkoholöverkonsumtion, 
övervikt och stora problem med halsbränna. Den klassiska behandlingen av esofaguscancer är 
att operera bort tumören inklusive matstrupen och ersätta den genom att skapa en tub av 
magsäcken som förs upp i bröstkorgen. Detta är en mycket stor och krävande operation som 
leder till komplikationer i 30-50% av fallen, och ger ungefär 25-30% chans till 5-
årsöverlevnad. På senare år har forskning visat att det är fördelaktigt att ge behandling med 
cellgifter eller kombination av cellgifter och strålbehandling innan operationen utförs. På så 
sätt har chansen till långtidsöverlevnad ökat något. Avsikten är att tumören ska krympa inför 
operation varvid chansen ökar att den går att operera bort i sin helhet. Behandlingen minskar 
också risken för spridning av tumören till lymfkörtlar. Risken med att ge förbehandling är att 
komplikationer efter operation kan öka och att patienten kan bli så påverkad av behandlingen 
att operationen inte kan utföras. Det är visat att de patienter som svarar på behandlingen 
genom att tumören krymper har klart bättre prognos än de som inte svarar. I vissa länder 
används cellgifter som förbehandling och i andra kombinerade behandlingar med strålning. 
Innan vår studie gjordes fanns bara två randomiserade studier som jämfört cellgifter med 
kombinations-behandling.  
Vår grupp har under 2006-2013 randomiserat 181 patienter i Sverige och Norge med 
operabel esofaguscancer till förbehandling med cellgifter eller kombinationsbehandling. 
Arbete I är en analys av de första 90 dagarna efter operationen. Resultaten visar att båda 
grupperna får komplikationer lika ofta, men att utgången var klart sämre i gruppen som fått 
strålning inför operation. Arbete III är en analys av hur många patienter som svarat på 
behandlingen med krympning av tumören och av 3-årsöverlevnad. Resultaten visar att 
kombinationsbehandling ger klart ökad krympning av tumören men vi såg inte att det ledde 
till någon överlevnadsvinst. Arbete II är en analys av 70 patienter som opererats på 
Karolinska Universitetssjukhuset för esofaguscancer med sammankoppling av magsäck och 
matstrupe gjord ovanför bröstkorgen via halsen. Resultaten visar att den delen av magsäcken 
som används i kopplingen ofta får ganska höga stråldoser innan operationen, vilket kan 
påverka läkningen. Vi såg också att de patienter som behandlats med 
kombinationsbehandling inför operation hade större risk att utveckla allvarliga 
komplikationer jämfört med övriga. Arbete IV är en sammanställning av alla patienter som 
registrerats i Sveriges Nationella Register för Esofagus- och Ventrikelcancer, vilket är mer än 
95% av alla cancerfall under denna period. Totalt inkluderades 1020 patienter som delades in 
i grupper beroende på behandling. Resultaten visade att förbehandling med cellgifter eller 
kombinationsbehandling ger ökad chans för krympning av tumören men ingen 
överlevnadsvinst för patienter med tumörtypen körtelcancer. De som hade skivepitelcancer 
och förbehandling hade ökad överlevnad. Båda typerna av förbehandling ökade dock risken 
för komplikationer och dödsfall i samband med operation.  
Sammanfattningsvis visar denna avhandling att förbehandling med cellgifter och strålning 
ger ökad tumörkrympning och överlevnad för patienter med skivepitelcancer men troligen till 
priset av ökade risker i samband med operation. För patienter med körtelcancer sågs inte 
någon överlevnadsvinst av tilläggsbehandling med strålning. 
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8 FUTURE PERSPECTIVES 
We will continue to study neoadjuvant treatment for esophageal and junctional carcinomas. 
Patient selection is an interesting issue to investigate further. The factors that determine a 
patient’s response to neoadjuvant treatment will be studied. Patients with histological 
complete response can be compared with non-responders possibly in a case control study. 
Another interesting issue is the use of biochemical markers to identify patients that will 
respond to the neoadjuvant treatments. Methods for determining complete response without 
esophagectomy, and possibly avoid surgery in these patients, will be developed.  
With the introduction of minimally invasive surgical techniques, and improved postoperative 
recovery with modern approaches and enhanced recovery programs, the use of adjuvant 
treatment could change in the future. The planning of the neoadjuvant radiation field in 
relation to the site of the anastomosis on the gastric fundus is an important issue.  
Concerning histological tumor type it is now clear that esophageal AC and SCC are to be 
considered as two different cancers and studied separately in future trials. Definitive 
chemoradiotherapy for patients with SCC is a very interesting option for the future. 
Optimization of the nCRT and nCT strategies will continue and hopefully new drugs can be 
developed to increase the chances for survival in esophageal cancer.  
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